- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-----------
FORM 10-K
-----------
/X/ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
FOR THE FISCAL YEAR ENDED JUNE 30, 1998
COMMISSION FILE NUMBER: 0-4136
-----------
LIFECORE BIOMEDICAL, INC.
(Exact name of registrant as specified in its charter)
MINNESOTA 41-0948334
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification No.)
3515 LYMAN BOULEVARD
CHASKA, MINNESOTA 55318-3051
(Address of principal executive offices)
Registrant's telephone number, including area code: (612) 368-4300
Securities registered pursuant to Section 12(b) of the Act: NONE
Securities registered pursuant to Section 12(g) of the Act:
COMMON STOCK ($.01 STATED VALUE)
(Title of Class)
-----------
Indicate by check mark whether the Registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports) and (2) has been subject to such
filing requirements for the past 90 days. Yes /X/ No / /
Indicate by check mark if disclosure of delinquent filers pursuant to
Item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best of Registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. / /
The aggregate market value of the voting stock held by non-affiliates of
the Registrant was approximately $130,000,000 at August 14, 1998 when the last
sale price of such stock, as reported by the Nasdaq National Market, was $10.50.
The number of shares outstanding of the Registrant's Common Stock, $.01 stated
value, as of August 14, 1998 was 12,373,122 shares.
-----------
DOCUMENTS INCORPORATED BY REFERENCE
1. Proxy Statement to be filed with the Commission within 120 days after the
end of the Registrant's fiscal year.
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
1
PART I
ITEM 1. BUSINESS
GENERAL
Lifecore Biomedical, Inc. ("Lifecore" or the "Company") develops,
manufactures and markets medical and surgical devices through its two divisions,
the Hyaluronate Division and the Oral Restorative Division. Further information
about Lifecore can be obtained from Lifecore's internet site at
www.lifecore.com.
The Company's Hyaluronate Division is principally involved in the
development and manufacture of products utilizing hyaluronate, a naturally
occurring carbohydrate which moisturizes or lubricates the soft tissues of the
body. The Hyaluronate Division's primary development project involves
INTERGEL-TM- Adhesion Prevention Solution ("INTERGEL Solution"), formerly
referred to as LUBRICOAT-Registered Trademark- 0.5% Ferric Hyaluronate Gel.
INTERGEL Solution is a second generation product with potential application in
reducing the incidence of post-surgical adhesions. INTERGEL Solution is
intended to reduce the incidence of fibrous tissue adhesions, which commonly
form as part of the body's natural healing process when tissues or organs are
subject to accidental or surgical trauma. Particularly with respect to
abdominal, cardiovascular, orthopedic, reproductive, and thoracic surgeries,
these adhesions may cause internal complications that often require costly
post-surgical intervention. Government sources recently estimated the annual
cost of treatment of adhesion complications in the female lower abdomen alone, a
common site for the occurrence of adhesions, at $2 billion in the United States.
On June 1, 1998, the Company's exclusive worldwide marketing partner, Ethicon,
Inc., a Johnson & Johnson Company, began limited marketing of INTERGEL Solution
in Europe.
The Company produces hyaluronate through a proprietary fermentation
process. Currently, the primary commercial use for the Company's hyaluronate is
as a component in ophthalmic surgical solutions for cataract surgery and for
veterinary applications. Lifecore is pursuing other applications of hyaluronate
through corporate partners for drug delivery and wound care applications. The
Company also is leveraging its hyaluronate manufacturing skills to provide
specialized contract aseptic manufacturing services.
The Company's Oral Restorative Division markets a comprehensive line of
titanium-based dental implants for the replacement of lost or extracted teeth.
In May 1992, the Company acquired the Sustain Dental Implant System from
Bio-Interfaces, Inc. ("BII") and subsequently, in July 1993, acquired Implant
Support Systems, Inc. ("ISS"), the manufacturer of the Restore Dental Implant
System and the ISS line of compatible components. The Company has enhanced and
expanded these product lines since their acquisition. The Oral Restorative
Division also manufactures and markets tissue regeneration products for the
restoration of bone deterioration resulting from periodontal disease and tooth
loss. In May 1997, Lifecore acquired the TefGen-Registered Trademark- product
line from Bridger Biomed, Inc. ("Bridger"). The acquisition expanded and
complemented the growing line of tissue regenerative products by adding a
nonresorbable membrane to address the current clinical practice referred to as
guided tissue regeneration. In June 1997, Lifecore expanded its tissue
regeneration business to include soft tissue applications with the addition of
AlloDerm-Registered Trademark- Dermal Graft, which the Company distributes on an
exclusive basis to the U.S. dental market for LifeCell Corporation ("LifeCell").
This Division's products are marketed in the United States through the Company's
direct sales force; in Italy through the Company's subsidiary, Lifecore
Biomedical SpA; and in other countries through distributors.
HYALURONATE DIVISION
BACKGROUND
Hyaluronate is a critical, naturally occurring carbohydrate component of
physiological fluids that lubricate, moisturize or otherwise protect the body's
soft tissues. Due to its widespread presence in tissues and its high degree of
biocompatibility, the Company believes that hyaluronate can be used for a wide
variety of medical applications.
Hyaluronate (also referred to as hyaluronan, hyaluronic acid and sodium
hyaluronate) was first demonstrated to have commercial medical utility as a
viscoelastic (elastic yet fluid) solution in cataract surgery. In this
application, its use for coating and lubricating of tissues during the
implantation of intraocular lenses dramatically improved the existing surgical
success rates. An ophthalmic hyaluronate product, produced by extraction from
rooster comb tissue, initially became commercially available in the United
States in 1981. Hyaluronate-based products, produced both by rooster comb
extraction and by fermentation processes such as the Company's, have since
gained widespread acceptance among ophthalmologists and are currently used in
the majority of cataract extraction procedures in the world.
2
Other hyaluronate applications currently being investigated by Lifecore or
its partners include general surgery (prevention of post-surgical adhesions),
catheter guide-wire coatings and drug delivery (as a vehicle to carry wound
healing agents). The Company believes that the use of hyaluronate for the
prevention of post-surgical adhesions currently represents the most significant
potential application for hyaluronate.
STRATEGY
The Company intends to use its proprietary fermentation process to be a
leader in the development of hyaluronate-based products for multiple
applications. Elements of the Company's strategy include the following:
- ESTABLISH STRATEGIC ALLIANCES WITH MARKET LEADERS. The Company will
continue to develop applications for products with partners who have strong
marketing, sales and distribution capabilities to end-user markets. The Company
currently has established relationships with Alcon Laboratories, Inc., an
indirect subsidiary of Nestle S.A. ("Alcon"), Bausch & Lomb Surgical, a division
of Bausch & Lomb, Inc. ("Bausch & Lomb Surgical"), Ethicon, Inc., a Johnson &
Johnson Company ("Ethicon"), Johnson & Johnson Medical, Ltd., a wholly-owned
subsidiary of Johnson & Johnson ("JJML"), and Mentor Ophthalmics Inc.
("Mentor"), market leaders in the ophthalmics and surgical products fields.
- EXPAND MEDICAL APPLICATIONS FOR HYALURONATE. The Company is currently
pursuing abdominal surgery, veterinary, drug delivery and wound care
opportunities. Due to the growing knowledge of the unique characteristics of
hyaluronate, the Company intends to continue to identify and pursue further uses
for hyaluronate in medical applications.
- MAINTAIN FLEXIBILITY IN PRODUCT DEVELOPMENT AND SUPPLY RELATIONSHIPS.
The Company's vertically integrated development and manufacturing capabilities
allow it to establish a variety of relationships with large corporate partners.
The Company's role in these relationships extends from supplier of raw materials
to manufacturer of aseptically-packaged finished products. In addition, the
Company may develop its own proprietary products.
- LEVERAGE HYALURONATE MANUFACTURING SKILLS. The Company is using its
viscous fluid handling and aseptic packaging experience gained in producing
hyaluronate to provide specialized contract aseptic manufacturing services.
HYALURONATE DIVISION PRODUCTS
The following chart summarizes the principal products and development
projects of the Hyaluronate Division, along with their applications and the
companies with which Lifecore has related strategic alliances:
- -----------------------------------------------------------------------------------
PRODUCT STRATEGIC ALLIANCE MARKET STATUS*
- -----------------------------------------------------------------------------------
GENERAL SURGERY
INTERGEL-TM- Lifecore's proprietary Adhesion Pending U.S.
Adhesion product under development; prevention FDA Pre-Market
Prevention Solution Ethicon has exclusive Approval,
worldwide marketing rights marketed by
for adhesion prevention Ethicon in
applications and orthopedics Europe for
abdominal
applications
- -----------------------------------------------------------------------------------
OPHTHALMIC
Viscoat-Registered Lifecore supplies Cataract Commercial
Trademark- proprietary hyaluronate surgery sales since
Ophthalmic powder for inclusion in 1983
Viscoelastic Alcon Laboratories'
Solution viscoelastic solution
Amvisc-Registered Lifecore supplies finished Cataract Lifecore export
Trademark- and syringes to Bausch & Lomb surgery shipments
Amvisc Surgical, which markets the commenced in
Plus-Registered products December 1995;
Trademark- U.S. sales
Ophthalmic pending Bausch
Solutions & Lomb Surgical
PMA supplement
approval
- -----------------------------------------------------------------------------------
3
- -----------------------------------------------------------------------------------
PRODUCT STRATEGIC ALLIANCE MARKET STATUS*
- -----------------------------------------------------------------------------------
Lurocoat-Registered Lifecore supplies its Cataract Lifecore export
Trademark- proprietary product to surgery shipments
Ophthalmic Mentor Ophthalmics, Inc., commenced in
Solution for marketing on a non- June 1997
exclusive basis outside the
U.S. Product is also
supplied on a non-exclusive
basis to several other
ophthalmic companies
Caprogel-TM- Lifecore supplies syringes Ocular Orphan
Topical to Orphan Medical, Inc., bleeding Medical's human
Aminocaproic Acid which markets the product (hyphema) clinical trials
commenced in
1994
- -----------------------------------------------------------------------------------
WOUND MANAGEMENT Lifecore supplies process Wound JJML commenced
Wound healing development services and management clinical trials
agent hyaluronate powder to in 1997
Johnson & Johnson Medical,
Ltd. for use as a delivery
vehicle
- -----------------------------------------------------------------------------------
OTHER APPLICATIONS
MAP-5-TM- Embryo Lifecore supplies Veterinary Commercial
Cryopreservation hyaluronate in vials to cryopreserv sales since
Solution Vetrepharm, Inc., which ation, 1994
markets the product traumatic
arthritis
- -----------------------------------------------------------------------------------
* For many of the products or projects listed above, government regulatory
approvals and significant development work are required before commercial sales
can commence in the United States or elsewhere. See "Government Regulation." No
assurance can be given that such products will be successfully developed or
marketed.
ADHESION PREVENTION DEVELOPMENT PROJECT WITH ETHICON
The Company is developing a ferric hyaluronate product, INTERGEL-TM-
Adhesion Prevention Solution for potential application in reducing the incidence
of post-surgical adhesions. Ethicon has worldwide, exclusive distribution
rights for INTERGEL Solution.
Following surgical procedures fibrous tissue, or adhesions, commonly form
as part of the body's natural healing process resulting from trauma to tissues
or organs during surgery. Particularly with respect to abdominal,
cardiovascular, orthopedic, reproductive and thoracic surgeries, these adhesions
may cause internal complications that require costly additional surgical
intervention. For example, adhesions following abdominal surgery can cause
infertility, life threatening bowel obstructions, or complicate subsequent
surgical interventions. The Company believes that successful penetration of
this market will require a product with low toxicity, easy application, high
procedural flexibility, broad effectiveness, and appropriate pricing.
LAPAROTOMY. Prior to 1994 Lifecore and Ethicon were jointly developing an
anti-adhesion project. However, in 1994, Lifecore assumed responsibility for
completion of this project in order to accelerate development of the
anti-adhesion project. Lifecore subsequently completed the pre-clinical studies
and submitted an application to the United States Food and Drug Administration
("FDA") for an Investigational Device Exemption ("IDE") to begin human clinical
trials to evaluate the safety and efficacy of INTERGEL Solution. In April 1995,
the FDA approved the IDE. A pilot human clinical trial, involving 23 female
patients undergoing peritoneal cavity surgery with preservation of fertility,
was completed at a single United States clinical center in December 1995.
Patients were randomly selected to receive either INTERGEL Solution or a control
solution applied in a final step prior to completion of surgery by laparotomy
(conventional, or open surgery). The primary goals of the pilot study were the
preliminary assessment of the safety of INTERGEL Solution and an evaluation of
the experimental clinical protocol. A secondary goal was the preliminary
assessment of the effectiveness of INTERGEL Solution in reducing post-surgical
adhesions by second-look laparoscopy. Second-look laparoscopy is a standard
surgical practice with fertility patients, and consists of a less invasive
follow-up evaluation of the patients' internal abdominal anatomy using
microsurgical technology. The laparoscopy enabled clinicians to gather data
visually comparing post-surgical adhesions in the two patient treatment groups.
Analysis of the pilot clinical data indicated that patients who received
INTERGEL Solution experienced a 45% lower incidence of a broad range of
4
adhesions than control patients (p Less than 0.02). Further, the study
showed that when adhesions did occur, those of the INTERGEL Solution patient
group were significantly less extensive and less severe than those of the
control group (p Less than 0.01). Finally, physicians using the test
material indicated that it was easily incorporated into current clinical
procedures.
Based on these results, the Company initiated a pivotal human clinical
trial in March 1996. That study is nearing completion and involves
approximately 280 patients in a blinded study at approximately twelve clinical
sites in the United States and five clinical sites in Europe. These patients
undergo a similar randomized treatment protocol and are evaluated for adhesion
formation at 24 abdominal and pelvic sites by second-look laparoscopy. Initial
evaluations of the pivotal trial confirm the trend of statistical significance
observed in the pilot trial. The Company has begun the application process for
FDA Pre-Market Approval ("PMA") in June 1998. There can be no assurance that
the results of the pivotal trial will be accepted by the FDA as sufficient to
grant the Company a PMA. See "Government Regulation."
LAPAROSCOPY. Subsequently, the companies began a second series of human
clinical trials to evaluate INTERGEL Solution as an adjunct in less invasive,
microsurgical procedures. Since laparoscopic procedures are rapidly becoming a
preferred surgical interventional method, the companies wished to ensure the
utility of INTERGEL Solution under the more physically restrictive demands of
laparoscopic techniques in comparison to laparotomy techniques. A pilot trial
has been completed showing results similar to that of the product in the pilot
laparotomy trial. FDA has subsequently allowed the expansion of patient
enrollment in that trial to test for clinical significance in an ongoing
multi-center evaluation.
In August 1994 when responsibility for development of this project was
shifted to Lifecore, the Company and Ethicon entered into a Conveyance, License,
Development and Supply Agreement (the "Ethicon Agreement") to carry out the
shift of responsibility. The Ethicon Agreement transferred to the Company the
intellectual property developed to date from the anti-adhesion project,
including pending patent rights and data from research, product development,
clinical safety and efficacy, and marketing evaluations. The Company assumed
responsibility for continuing the development project, including conducting
human clinical trials with INTERGEL Solution. Furthermore, the Company granted
Ethicon exclusive worldwide marketing rights to INTERGEL Solution for
post-surgical adhesion prevention and certain orthopedic applications in return
for an exclusive supply contract through 2008 with provisions for renewal. The
Company currently receives certain technical support in return for a specified
annual fee under the provisions of an associated consulting agreement. Under
this agreement, the primary Ethicon scientist responsible for supervising the
anti-adhesion project since its inception reports directly to Lifecore
management.
OPHTHALMIC APPLICATIONS
CATARACT SURGERY. Currently, the primary commercial application for the
Company's hyaluronate is in cataract surgery. During the process of cataract
surgery, hyaluronate, in the form of a viscoelastic solution, is used to coat
and lubricate the anterior chamber of the eye during intraocular lens
implantation. These solutions have been shown to reduce surgical trauma and
thereby contribute to more rapid recovery with fewer complications than were
experienced prior to the use of viscoelastics. The Company currently sells
hyaluronate for this application to six customers, including Alcon, Bausch &
Lomb Surgical and Mentor. Alcon and Bausch & Lomb Surgical are two of the
leading producers of ophthalmic surgical products in the world. In February
1996, the Company entered into a private label manufacturing agreement with
Mentor to supply the Lurocoat solution on an exclusive basis in the United
States and Canada and on a non-exclusive basis elsewhere for use in ophthalmic
surgery. The Company also has three other agreements to supply Lurocoat
solution under private label relationships outside the United States and Canada
for this application.
Hyaluronate-based products are used in the majority of cataract surgeries
in the world. The Company estimates that the worldwide market for hyaluronate
for cataract surgery, on a patient cost basis, is approximately $160 million per
year and is relatively stable. However, the market share of products using
fermented hyaluronate has increased relative to the market share of products
using hyaluronate extracted from rooster combs.
Alcon purchases the Company's hyaluronate for inclusion in
Viscoat-Registered Trademark- Ophthalmic Viscoelastic Solution, which is used
during cataract surgery. The Company's relationship with Alcon and its
predecessors commenced in 1983, when the Company's hyaluronate was specified as
a raw material component of the Viscoat product, which received clearance from
the FDA in 1986. Until 1990, Alcon's predecessors had the exclusive rights to
purchase the Company's hyaluronate for ophthalmic applications. In 1990, the
arrangement with Alcon became non-exclusive. Since that time, sales of
hyaluronate to Alcon have continued to be made pursuant to supply agreements.
The current Alcon supply agreement, as renewed in November 1994, is for a term
of four years through December 31, 1998. The Company is currently in
discussions with Alcon and does not foresee any material issues in renewing the
agreement. See "Management's Discussion and Analysis of Financial Condition and
Results of Operations."
5
In December 1994 the Company entered into a supply agreement with Bausch &
Lomb Surgical. Under the agreement, the Company has been selling its hyaluronate
to Bausch & Lomb Surgical for export in packaged syringes in connection with two
of Bausch & Lomb Surgical's ophthalmic viscoelastic surgical products,
Amvisc-Registered Trademark- and Amvisc Plus-Registered Trademark- Ophthalmic
Solutions. The Company has validated its manufacturing facility to produce these
products, and Bausch & Lomb Surgical has filed a PMA supplement with the FDA in
1998 to allow the Company to manufacture these products for U.S. sale. FDA
action on that supplement request is expected during the Fall of 1998. The sale
by Bausch & Lomb Surgical in the United States of Amvisc and Amvisc Plus
syringes supplied by the Company is dependent upon such FDA clearance. In
December 1995 Bausch & Lomb Surgical commenced shipments of finished products
supplied by the Company to Europe.
The Company is in the process of independently developing its own
viscoelastic solution, Lurocoat Solution, and has received an IDE from the FDA
to clinically evaluate that product for ophthalmic surgical use in the United
States. The Company has entered into a multi-year private label manufacturing
agreement with Mentor, under which the Company will manufacture the Lurocoat
product in syringes under Mentor's trade name for sale on a non-exclusive basis
outside the United States. The Company received CE marking for Lurocoat
solution during fiscal year 1997. The Company also has three other private
label agreements to supply Lurocoat solution to others outside the United States
and Canada. Export shipments of Lurocoat solution began in fiscal year 1997.
OTHER APPLICATIONS
In its work with hyaluronate, the Company developed specialized packaging
skills with materials that, due to their perishable nature or complex viscous
handling properties, often can not be sterilized in a conventional manner and
required rigorous aseptic manufacturing and packaging protocols. The Company is
leveraging these skills to initiate non-ophthalmic development projects for the
manufacture of other hyaluronate and non-hyaluronate products in other medical
areas.
One such application is the use of hyaluronate as a drug delivery vehicle
for a product being developed by Johnson & Johnson Medical, Ltd. ("JJML"). JJML
is developing a product that utilizes the Company's hyaluronate and process
development expertise to produce a drug delivery vehicle to enhance topical
wound healing. During fiscal 1997, JJML entered pre-clinical trials with this
product.
The Hyaluronate Division undertakes its own product development activities
for both hyaluronate-based and non-hyaluronate-based applications, as well as on
a contract basis with certain clients. The majority of outside projects are
initiated by a client to demonstrate that the Company's hyaluronate is suitable
for a particular medical application. Suitability is often measured by detailed
specifications for product characteristics such as purity, stability, viscosity,
and molecular weight, as well as efficacy for a particular medical application.
The Company currently manufactures Vetrepharm, Inc.'s MAP-5-TM- Embryo
Cryopreservation Solution, an aseptically-packaged hyaluronate solution, for the
cryopreservation of fertilized animal embryos. MAP-5 Solution is used to
preserve the embryos for transportation to local veterinarians. Sales to
Vetrepharm, Inc. have been made since 1994 pursuant to annual purchase orders
which specify the quantity and unit price.
An example of a non-hyaluronate development project is the manufacture of
Orphan Medical's Caprogel-TM- Topical Aminocaproic Acid. Orphan Medical is
evaluating the product in clinical trials for treatment of hyphema, a form of
ocular trauma.
There can be no assurance that products currently under development by the
Company or others will be successfully developed or, if so developed, will be
successfully and profitably marketed.
ORAL RESTORATIVE DIVISION
BACKGROUND
Dental implants are increasingly accepted as a replacement for missing or
extracted teeth and serve as supports for dentures, crowns, and bridges. In
comparison to conventional restorative procedures, dental implants are
surgically placed directly into the jawbone in a manner simulating the anchoring
of a tooth by its root. This better maintains underlying bone structure and
provides superior fixation of restorations, minimizing loosening of fixtures
against surrounding teeth and gingiva. Typically
6
constructed of titanium in a cylindrical or flattened shape, dental implants
generally are categorized by shape and method of implantation. For example, the
threaded cylinder implant is screwed into the jawbone, while an alternate form,
the press-fit cylinder, is placed into a precision-drilled hole with a friction
fit. Additionally, various implant styles may be spray coated with
hydroxylapatite or metal to enhance bone fixation. The Company believes the
current worldwide dental implant market is approximately $460 million.
Bone graft substitutes are used for the restoration of hard tissue that has
deteriorated due to periodontal disease and tooth loss. Historically, bone
needed to fill holes or restore bone loss in a patient was only available from
cadavers, live donor bone or autologous bone (from another part of the patient's
body). These sources have limitations related to quality and convenience. The
Company has developed a patented process for the synthetic production of
hydroxylapatite, the major inorganic constitute of natural bone. The Company's
hydroxylapatite products provide surgeons with a readily available synthetic
bone substitute of consistent quality at a competitive cost for periodontal and
oral surgery applications. While the current market for bone substitute products
is limited (approximately $5 million annually in the United States), the
addition of supplemental hard tissue regeneration products has expanded the
market to approximately $25 million in the United States. The Company's
TefGen-Registered Trademark- Regenerative Membrane and Capset-TM- Calcium
Sulfate Bone Graft Barrier address this market opportunity. Similarly, a market
for soft tissue regenerative products has developed to address the area of soft
tissue replacement in adding to or replacing gingival tissue. The estimated
U.S. market potential for a soft tissue regenerative product is approximately
$50 million. AlloDerm-Registered Trademark- Dermal Graft addresses this market
opportunity.
STRATEGY
The Company intends to be a leader in the oral restorative surgical
products industry. The Company's strategies for achieving this goal are as
follows:
- Develop a broad line of dental implants and related dental surgery
support products which facilitate the transition from competitive
systems to a broad-based Lifecore system.
- Develop and deliver unique educational programs and materials aimed at
participating dentists and their staffs to facilitate the conversion
from traditional dental treatment options to those involving dental
implant and tissue regeneration therapy.
- Develop and implement cooperative marketing programs with the
dentists' referral groups for the purpose of creating increased
awareness of dental implant and tissue regeneration therapy and
expanding the clinicians practice.
ORAL RESTORATIVE DIVISION PRODUCTS
The following chart summarizes the principal products of the Company's Oral
Restorative Division:
- ------------------------------------------------------------------------------
PRODUCT MARKET STATUS
- ------------------------------------------------------------------------------
Sustain-Registered Replacement of lost or extracted Commercial sales
Trademark- and teeth
Restore-Registered
Trademark- Dental
Implant Systems
- ------------------------------------------------------------------------------
Implant Support Systems Precision oral restorative Commercial sales
components compatible with
implants
- ------------------------------------------------------------------------------
Capset-TM- Calcium For use with natural and Commercial sales
Sulfate Bone synthetic bone graft materials as
Graft Barrier a resorbable barrier cap and/or
binding agent
- ------------------------------------------------------------------------------
TefGen-Registered Nonresorbable membrane for guided Commercial sales
Trademark- tissue regeneration
Regenerative
Membrane
- ------------------------------------------------------------------------------
Hapset-Registered Repair of jawbone structure Commercial sales
Trademark-
Hydroxylapatite Bone
Graft Plaster
- ------------------------------------------------------------------------------
Orthomatrix-Registered Repair of jawbone structure Commercial sales
Trademark- Non-resorbable
Hydroxylapatite Bone
Graft Substitute
- ------------------------------------------------------------------------------
AlloDerm-Registered For use in gingival tissue Commercial sales
Trademark- Dermal replacement or augmentation
Graft surgery
- ------------------------------------------------------------------------------
7
IMPLANT PRODUCTS
The Company offers two primary dental implant systems, the Restore Dental
Implant System and the Sustain Dental Implant System.
The Restore System is based on a classic threaded titanium implant design
that pioneered the commercialization of these devices in general oral
restorative surgery. In July 1993, the Company acquired this implant design in
connection with its acquisition of Implant Support Systems, Inc., a manufacturer
of dental implant products. The Company has since enhanced and expanded the
original ISS line into a broad range of implant options, marketed under the
Restore System name. Included in the ISS acquisition was a line of dental
implant prosthetic components that the Company continues to market under the
Implant Support Systems brand. These components are compatible and
interchangeable with several other dental implant manufacturers' systems, as
well as miscellaneous dental implant support products, permitting the Company to
market its products to dental offices that currently use competitors' implant
systems.
The Sustain System is based on a newer innovative design that embraces both
threaded and press-fit cylinder formats with added "bone-like" hydroxylapatite.
In May 1992, the Company acquired the basic Sustain System from
Bio-Interfaces, Inc. after serving as an exclusive distributor for the Sustain
System since 1990. The Sustain System, like the Restore System, is complemented
by a complete line of prosthetic components.
Lifecore has enhanced and expanded both of these lines, creating numerous
new products with a combination of innovative features from both systems. This
gives the Company one of the broadest lines in the oral restorative industry and
offers practitioners maximum flexibility in choice of treatment modalities with
over 1,100 products.
BONE AND SOFT TISSUE REGENERATION PRODUCTS
The Company offers five products which address various bone and tissue
regeneration procedures.
CAPSET-TM- Calcium Sulfate Bone Graft Barrier received 510(k) clearance and
was introduced to the market in 1995. The product is based on a calcium sulfate
plaster technology developed by and licensed from the U.S. Gypsum Corporation.
The business unit of U.S. Gypsum that supplied Lifecore with the raw material
and exclusive license rights to its dental use was purchased during the
Company's fiscal year 1997 by Wright Medical, Inc., an orthopedic products
manufacturer based in Memphis, Tennessee. Wright Medical and Lifecore have
agreed to maintain the technology and license agreement. CAPSET Barrier allows
the clinician to more efficiently use demineralized freeze-dried bone grafts to
restore missing bone, particularly in periodontal defects, without resorting to
more elaborate treatment techniques or no treatment at all.
TefGen-Registered Trademark- Regenerative Membrane technology was acquired
by the Company from Bridger Biomed, Inc. in May 1997. This non-resorbable
membrane is based on nanoporous PTFE BIOMATERIALS ("nPTFE"); competitive with
the market's leading product produced by W.L. Gore. TefGen Regenerative
Membrane allows the dental surgeon to cover a treated defect in bone and prevent
the invasion of soft tissue while the slower growing bone tissue underneath has
time to establish itself.
HAPSET-Registered Trademark- Hydroxylapatite Bone Graft Plaster is a
moldable, partially resorbable form of hydroxylapatite graft substitute that can
be contoured to fill a bone defect during surgery. It consists of the Company's
hydroxylapatite particle in a carrier of the same calcium sulfate plaster used
in CAPSET Barrier.
ORTHOMATRIX-Registered Trademark- Non-resorbable Hydroxylapatite Bone Graft
Substitute is a hydroxylapatite particle that can be used in place of
freeze-dried allograft bone or the patient's own bone in defects where permanent
graft presence is desired.
AlloDerm-Registered Trademark- Acellular Dermal Graft is freeze-dried,
chemically processed, human donor skin that can be used as a substitute for soft
tissue grafts taken from the roof of the patient's mouth. In June 1997,
Lifecore entered into an exclusive U.S. sales and distribution agreement with
LifeCell Corporation to market and distribute AlloDerm Graft in the dental
market. The product provides soft tissue for adding or replacing gingival
tissue without the second-site surgery and patient discomfort associated with
palatal (roof of mouth) harvesting of graft tissue.
8
PRODUCT DEVELOPMENT
The Oral Restorative Division is also involved in product development
activities to improve existing components and packaging and to add new
components to the dental implant systems. These development activities enhance
the suitability and ease of use of the products for specific surgical
applications and reflect changing trends in dental implant technology. There can
be no assurance, however, that products which are currently under development by
the Company will be successfully developed, or if so developed, will be
successfully and profitably marketed.
SALES AND MARKETING
HYALURONATE DIVISION PRODUCTS
The Company generally markets and distributes its hyaluronate products to
end-users through corporate partners. The Company sells hyaluronate to these
partners in a variety of forms, including powders, gels and solutions which are
packaged either in bulk jars, vials, or syringes. The Company sells its
ophthalmic grade hyaluronate powder to Alcon for Alcon's Viscoat solution and
supplies Bausch & Lomb Surgical's Amvisc products for sale in Europe. Mentor
Ophthalmics, Inc. will provide exclusive marketing of the Lurocoat viscoelastic
for ophthalmic surgery outside of the United States. The Company also has three
other private label agreements to supply Lurocoat viscoelastic to others outside
the United States and Canada. The Company also sells vials of hyaluronate
solution for veterinary embryo cryopreservation to Vetrepharm, Inc.
The Company has an agreement with Ethicon for exclusive distribution of
INTERGEL Solution. The Company believes that Ethicon is the worldwide market
leader in the area of surgical products and has one of the largest marketing and
sales forces in the industry. Commercialization of INTERGEL Solution is
dependent on completion of clinical trials, receipt of FDA marketing clearance,
successful manufacturing of commercial quantities, and the efforts of Ethicon to
develop the market for the product. No assurance can be given that any or all of
these conditions will be met.
The Company also sells various forms of medical grade hyaluronate directly
to third parties for development and evaluation of new applications to be
marketed and distributed through those companies' distribution systems or a
jointly developed distribution system.
ORAL RESTORATIVE DIVISION PRODUCTS
The Company is focused on expanding its product line in the Oral
Restorative Division, improving product quality, and developing an appropriate
infrastructure to support sales growth. Management of the Company believes that
the dental implant market is highly specialized and that its sales force must
have extensive knowledge about the products. The products are marketed to oral
surgeons, periodontists, implantologists, prosthodontists, general dental
practitioners, and dental laboratories. Accordingly, the Company believes that
it must maintain a direct sales force in the United States for proper
distribution of these products. The Company believes that because of their high
level of experience, its sales force offers better customer service, technical
support and regulatory control than could be achieved through an independent
distributor network in the United States. The Company employs twenty-two
individuals dedicated to sales in the United States and five U.S.-based
salespersons dedicated to international sales. The Oral Restorative Division
products are marketed internationally through 23 distributors. In addition, the
products are marketed in Italy through its subsidiary, Lifecore Biomedical SpA,
which currently utilizes eight sales agents.
The Company's marketing activities are designed to support its direct sales
force and include advertising and product publicity in trade journals, direct
mail catalogs, newsletters, continuing education programs, telemarketing, and
attendance at trade shows and professional association meetings. Industry
estimates indicate a need for replacement of approximately 100 million teeth in
the adult population of the United States. That represents a potential market
for implant companies such as Lifecore of approximately $20-30 billion.
MANUFACTURING
The commercial production of hyaluronate by the Company requires
fermentation, separation and purification capabilities, and aseptic packaging of
product in a variety of formats. In addition, the production of the INTERGEL
Solution requires high volume precision mixing of viscous fluids.
9
The Company produces its hyaluronate through a proprietary process of
fermentation. Until the introduction of the Company's medical grade hyaluronate,
the only commercial source for medical hyaluronate was through an animal
rendering process of extraction from rooster combs. The Company believed that
the rooster comb extraction method would not be capable of producing large
quantities of hyaluronate in an efficient manner if the use of medical grade
hyaluronate greatly increased. Consequently, the Company developed its
proprietary fermentation process for hyaluronate using existing knowledge of
other successful fermentation manufacturing processes. The Company believes that
the fermentation manufacturing approach is superior to rooster comb extraction
because of greater efficiency, flexibility, and better economies of scale in
producing large commercial quantities.
The Company has a recently expanded 110,000 square foot facility primarily
for the Company's proprietary hyaluronate manufacturing process. Several
corporate partners have required that the Company validate its manufacturing
capability to fulfill forecasted production requirements by creating additional
capacity and periodically operating at higher capacity levels. The Company
believes it has adequate current fermentation manufacturing capacity to meet
these needs.
The Company provides versatility in the simultaneous manufacturing of
various types of finished products. Currently, the Company supplies several
different formulations of hyaluronate (e.g., varied molecular weight fractions)
in powders, solutions and gels, and in a variety of finished packages, including
bulk jars, vials and syringes. The Hyaluronate Division is continuously
conducting development work relating to the techniques utilized in hyaluronate
manufacturing. Such development activity is designed to improve production
efficiencies and expand the Company's capabilities to achieve a wider range of
hyaluronate product specifications. The Company's specialized fluid handling and
aseptic packaging capabilities also provide the opportunity for the Company to
offer contract packaging for other technically challenging non-hyaluronate
fluids.
In anticipation of significant commercial demand for hyaluronate products,
specifically INTERGEL Solution, the Company has expanded its warehouse and
distribution capabilities and its aseptic formulation and packaging facilities
for finished products. The scale-up of the aseptic operations requires the
purchase and validation of additional equipment and training of additional
personnel. See "Management's Discussion and Analysis of Financial Condition and
Results of Operations".
The Company's facility was designed to meet applicable regulatory
requirements and has been cleared by the FDA for the manufacture of both drug
and device products. The FDA periodically inspects the Company's manufacturing
systems, and requires conformance to the FDA's Quality Systems Regulations
("QSR"). In addition, the Company's corporate partners are required by the FDA
to conduct intensive regulatory audits of its facilities. The Company also
regularly contracts with independent regulatory consultants to conduct audits of
the Company's operations. The Company has received certification of conformance
to ISO 9001 Standards and Medical Device Directives, as well as the COMMISSION
EUROPEAN (CE) Mark of Conformity from TUV Product Services of Munich, Germany.
These approvals represent international symbols of quality system assurance and
compliance with applicable European Medical Device Directives, which greatly
assist in the marketing of the Company's products in the European Union.
The Company uses outside metal finishing vendors to produce its finished
dental implant devices and related components. The Company conducts its own
inspection of vendors and quality assurance and quality control functions
related to the implant devices and components and performs its own finished
packaging.
The Company purchases raw materials for its production of hyaluronate and
hydroxylapatite from outside vendors. While these materials are available from a
variety of sources, the Company principally uses limited sources for some of its
key materials to better monitor quality and achieve cost efficiencies. The key
raw material for CAPSET Barrier is supplied exclusively by Wright Medical, and
the Company believes such supplier is able to provide adequate amounts of the
raw materials for such product. The Company utilizes supply agreements with
Bridger Biomed, Inc. to supply the TefGen membrane product line and LifeCell
Corporation to supply the AlloDerm Dermal Graft product line.
COMPETITION
The competitors of the Company include major chemical, dental, medical, and
pharmaceutical companies, as well as smaller specialized firms. Many of these
companies have significantly greater financial, manufacturing, marketing, and
research and development resources than the Company.
10
HYALURONATE PRODUCTS
A number of companies produce hyaluronate products and thus directly or
indirectly compete with Lifecore or its corporate partners. Several companies
are pursuing anti-adhesion product development, including Alliance
Pharmaceuticals, Inc., Anika Therapeutics, Inc., Biomatrix, Inc., Focal, Inc.,
Genzyme Corporation ("Genzyme"), Gliatech, Inc., Life Medical Sciences,
Osteotech and W.L. Gore & Associates, Inc. Genzyme is developing two
hyaluronate-based formulations for surgical anti-adhesion applications which
would directly compete with the Company's INTERGEL Solution product, if and when
cleared for marketing by the FDA. Genzyme has begun to market one of those
products, Seprafilm-TM- bioresorbable membrane. A second, gel product, is in
development. If the products obtain commercial acceptance the Company's
prospects for INTERGEL Solution, if and when approved, may be adversely
affected.
In addition to Genzyme several companies produce hyaluronate through a
fermentation process including Bio-Technology General Corporation, Kyowa Hakko,
Nippon, Seikagaku, and Miles Laboratories. Genzyme currently sells a high
molecular weight hyaluronate which is manufactured through a fermentation
process, to the Company's ophthalmic customer, Alcon, for use in its
Provisc-Registered Trademark- solution. In addition, several companies
manufacture hyaluronate by using rooster comb extraction methods. These
companies primarily include Anika Therapeutics, Inc., Biomatrix, Inc.,
Chesapeake Biological Labs, Fidia SpA, and Pharmacia & Upjohn. The Company
believes that its patented fermentation process may offer production and
regulatory advantages over the traditional rooster comb extraction method. The
Company's competitors have filed or obtained patents covering aspects of
fermentation production or uses of hyaluronate. These patents may cover the same
applications as the Company's. Although there can be no assurance, the Company
believes that it does not infringe the patents of its competitors. See "Patents
and Proprietary Rights."
The Company believes that competition in the ophthalmic and medical grade
hyaluronate market is primarily based on product performance and manufacturing
capacity, as well as product development capabilities. Future competition may be
based on the existence of established supply relationships, regulatory
approvals, intellectual property, and product price. After a manufacturer has
taken a product through the FDA marketing approval process, a change in
suppliers can involve significant cost and delay because significant
manufacturing issues may be encountered and supplemental FDA review may be
required.
ORAL RESTORATIVE PRODUCTS
The dental implant market is also highly competitive. Major market
competitors include Sulzer Calcitek, Inc., Paragon, Implant Innovations, Inc.
and Nobel Biocare AB in combination with its pending merger with Steri-Oss. A
number of these competitors are established companies with dominant market
shares. The Company believes that competition in the dental implant market is
based primarily on product performance and quality, strong sales support, and
education.
The Company believes that its broad product line facilitates the conversion
of competitive implant users to a Lifecore system. In addition, the Company has
developed several innovative education and marketing support programs which are
designed to increase the client's implant business. The Company believes it has
established a strong reputation for quality products due to its stringent design
and inspection criteria. No assurance can be given, however, that the Company
can effectively compete with manufacturers of dental implant systems having
larger, more established client bases.
The market for the Company's tissue regeneration products is also
competitive. The major competitors include Guidor AB (Guidor), Implant
Innovations, Inc., W. L. Gore (GORE-TEX), and Sulzer Calcitek Inc. (Biomend).
While the Company believes its product line and experienced sales representation
are an advantage in this area, no assurance can be given that it can gain
significant market share from its more established competitors.
PATENTS AND PROPRIETARY RIGHTS
The Company pursues a policy of obtaining patent protection for patentable
subject matter in its proprietary technology. In May 1985, the Company received
a United States patent covering certain aspects of its hyaluronate fermentation
process. The Company has also licensed a 1991 patent for the recombinant DNA
encoding of hyaluronate synthase, exclusively in the United States and
non-exclusively outside the United States. In August 1994, in connection with
the Ethicon Agreement, the Company was assigned a pending patent covering the
composition and use of INTERGEL Solution, with applications filed in the United
States, Australia, Brazil, Canada, Europe, Greece, and Japan. Subsequently, the
patent has been issued in Australia, Greece, Japan, and the United States. The
Company also has a United States patent covering the processes used in the
manufacture of hydroxylapatite and a second patent covering the hydroxylapatite
product produced by that process. The Company also licenses
11
patented technology used in the production of hydroxylapatite from Wright
Medical and the University of North Carolina. In conjunction with the purchase
of the TefGen membrane product line, the Company obtained the rights to the
patent for composition, manufacture and use of the nPTFE material.
The Company believes that patent protection is significant to its business.
However, if other manufacturers were to infringe on its patents, there can be no
assurance that the Company would be successful in challenging, or would have
adequate resources to challenge, such infringement. The Company also relies upon
trade secrets, proprietary know-how and continuing technological innovation to
develop and maintain its competitive position. There can be no assurance that
others will not obtain or independently develop technologies which are the same
as or similar to the Company's technologies. The Company pursues a policy of
requiring employees, temporary staff, consultants and customers (which have
access to some of its proprietary information) to sign confidentiality
agreements. There can be no assurance that the Company will be able to
adequately protect its proprietary technology through patents or other means.
The Company is aware that one or more of its competitors have obtained, or
are attempting to obtain, patents covering fermentation and other processes for
producing hyaluronate. Other patents have been, or may be, issued in the future
in product areas of interest to the Company. Although the Company is not aware
of any claims that its current or anticipated products infringe on patents held
by others, no assurance can be given that there will not be an infringement
claim against the Company in the future. The costs of any Company involvement in
legal proceedings could be substantial, both in terms of legal costs and the
time spent by management of the Company in connection with such proceedings. It
is also possible that the Company, to manufacture and market some of its
products, may be required to obtain additional licenses, which may require the
payment of initial fees, minimum annual royalty fees and ongoing royalties on
net sales. There can be no assurance that the Company would be able to license
technology developed by others, on favorable terms or at all, that may be
necessary for the manufacture and marketing of its products.
GOVERNMENT REGULATION
Government regulation in the United States and other countries is a
significant factor in the marketing of the Company's products and in the
Company's ongoing research and development activities. The Company's products
are subject to extensive and rigorous regulation by the FDA, which regulates the
products as medical devices and which, in some cases, requires a PMA, and by
foreign countries, which regulate the products as medical devices or drugs.
Under the Federal Food, Drug, and Cosmetic Act ("FDC Act"), the FDA regulates
clinical testing, manufacturing, labeling, distribution, sale, and promotion of
medical devices in the United States.
Following the enactment of the Medical Device Amendments of 1976 to the FDC
Act, the FDA classified medical devices in commercial distribution at the time
of enactment ("old devices") into one of three classes - Class I, II, or III.
This classification is based on the controls necessary to reasonably ensure the
safety and effectiveness of medical devices. Class I devices are those whose
safety and effectiveness can reasonably be ensured through general controls,
such as labeling, premarket notification (the "510(k) Notification"), and
adherence to FDA-mandated current QSR requirements for devices. Class II devices
are those whose safety and effectiveness can reasonably be ensured through the
use of special controls, such as performance standards, post-market
surveillance, patient registries, and FDA guidelines. Class III devices are
devices that must receive a PMA from the FDA to ensure their safety and
effectiveness. Ordinarily, a PMA requires the performance of at least two
independent, statistically significant clinical trials that demonstrate the
device's safety and effectiveness. Class III devices are generally
life-sustaining, life-supporting, or implantable devices, and also include most
devices that were not on the market before May 28, 1976 ("new devices") and for
which the FDA has not made a finding of substantial equivalence based upon a
510(k) Notification. An old Class III device does not require a PMA unless and
until the FDA issues a regulation requiring submission of a PMA application for
the device.
The FDA invariably requires clinical data for a PMA application and has the
authority to require such data for a 510(k) Notification. If clinical data are
necessary, the manufacturer or distributor is ordinarily required to obtain an
IDE authorizing the conduct of human studies. Once in effect, an IDE permits
evaluation of devices under controlled clinical conditions. After a clinical
evaluation process, the resulting data may be included in a PMA application or a
510(k) Notification. The PMA may be approved, or the 510(k) Notification cleared
by the FDA, only after a review process which may include requests for
additional data, sometimes requiring further studies.
If a manufacturer or distributor of medical devices can establish to the
FDA's satisfaction that a new device is substantially equivalent to what is
called a "predicate device," i.e., a legally marketed Class I or Class II
medical device or a legally
12
marketed Class III device for which the FDA has not required a PMA, the
manufacturer or distributor may market the new device. In the 510(k)
Notification, a manufacturer or distributor makes a claim of substantial
equivalence, which the FDA may require to be supported by various types of
information, including data from clinical studies, showing that the new device
is as safe and effective for its intended use as the predicate device.
Following submission of the 510(k) Notification, the manufacturer or
distributor may not place the new device into commercial distribution until an
order is issued by the FDA finding the new device to be substantially
equivalent. The FDA has no specific time limit by which it must respond to a
510(k) Notification. The 510(k) Notification process can take up to eighteen
months or more. The FDA may agree with the manufacturer or distributor that the
new device is substantially equivalent to a predicate device, and allow the new
device to be marketed in the United States. The FDA may, however, determine that
the new device is not substantially equivalent and require the manufacturer or
distributor to submit a PMA or require further information, such as additional
test data, including data from clinical studies, before it is able to make a
determination regarding substantial equivalence. Although the PMA process is
significantly more complex, time-consuming, and expensive than the 510(k)
Notification process, the latter process can also be expensive and substantially
delay the market introduction of a product.
Hyaluronate products are generally Class III devices. In cases where the
Company is supplying hyaluronate to a corporate partner as a raw material or
producing a finished product under a license for the partner, the corporate
partner will be responsible for obtaining the appropriate FDA clearance or
approval. Export of the Company's hyaluronate products generally requires
approval of the importing country.
The Sustain System and the Restore System, along with other dental
implants, are categorized as old Class III devices and are eligible for
marketing through 510(k) Notifications. The FDA, however, has proposed to
require PMAs for dental implants, and by law must confirm such implants as
Class III devices and require PMAs for them or reclassify them into Class II or
Class I. It is not known when the FDA will make this decision or whether it will
require PMAs for all, some or none of these implants. The Company began clinical
trials of its Sustain System under an IDE in 1990 in anticipation of the
possibility that the FDA would require submission of PMAs for dental implants
and believes it will have appropriate data to meet FDA requirements. The
Company's TefGen membrane product line is a Class II device. CAPSET Barrier,
HAPSET Plaster and ORTHOMATRIX Bone Graft Substitute have received market
clearance through 510(k) Notifications but are unclassified. Alloderm Dermal
Graft is regulated as a banked human tissue.
Other regulatory requirements are placed on a medical device's manufacture
and the quality control procedures in place, such as the FDA's device QSR
regulations. Manufacturing facilities are subject to periodic inspections by the
FDA to ensure compliance with device QSR requirements. The Company's facility is
subject to inspections as both a device and a drug manufacturing operation.
Other applicable FDA requirements include the medical device reporting
regulation, which requires that the Company provide information to the FDA on
deaths or serious injuries alleged to have been associated with the use of its
devices, as well as product malfunctions that would likely cause or contribute
to death or serious injury if the malfunction were to recur.
If the Company is not in compliance with FDA requirements, the FDA or the
federal government can order a recall, detain the Company's devices, withdraw or
limit 510(k) Notification clearances or PMA approvals, institute proceedings to
seize the Company's devices, prohibit marketing and sales of the Company's
devices, and assess civil money penalties and impose criminal sanctions against
the Company, its officers, or its employees.
There can be no assurance that any of the Company's clinical studies will
show safety or effectiveness; that 510(k) Notifications or PMA applications will
be submitted or, if submitted, accepted for filing; that any of the Company's
products that require clearance of a 510(k) Notification or approval of a PMA
application will obtain such clearance or approval on a timely basis, on terms
acceptable to the Company for the purpose of actually marketing the products, or
at all; or that following any such clearance or approval previously unknown
problems will not result in restrictions on the marketing of the products or
withdrawal of clearance or approval.
PRODUCT LIABILITY
Product liability claims may be asserted with respect to the Company's
products. In addition, the Company may be subject to claims for products of its
customers which incorporate Lifecore's materials. The Company maintains product
liability insurance coverage of $1.0 million per claim, with an aggregate
maximum of $2.0 million. The Company also carries a $10.0 million umbrella
insurance policy which also covers product liability claims. Lifecore Biomedical
SpA also carries product liability
13
insurance in the amount of $1.0 million per claim with an aggregate maximum of
$2.0 million. There can be no assurance that the Company will have sufficient
resources to satisfy product claims if they exceed available insurance coverage.
EMPLOYEES
As of July 31, 1998, the Company employed 158 persons on a full-time basis,
one part-time employee and five temporary employees. None of the Company's
employees is represented by a labor organization, and the Company has never
experienced a work stoppage or interruption due to labor disputes. Management
believes its relations with employees are good.
EXECUTIVE OFFICERS OF THE REGISTRANT
EXECUTIVE OFFICERS
The following sets forth the names of the executive officers of Lifecore,
in addition to information about their positions with Lifecore, their periods of
service in such capacities, and their business experience for at least the past
five years. There are no family relationships among them. All executive officers
named are elected or appointed by the Board of Directors for a term of office
from the time of election or appointment until the next annual meeting of
directors (held following the annual meeting of shareholders) and until their
respective successors are elected and have qualified.
JAMES W. BRACKE, PH.D. Dr. Bracke has been President and Chief Executive
Officer and a director since August 1983 and Secretary since March 1995. He
joined the Company in February 1981 as Senior Research Scientist.
DENNIS J. ALLINGHAM. Mr. Allingham was appointed Executive Vice President
in November 1997. He has been Chief Financial Officer of the Company since
February 1996. Mr. Allingham has also been General Manager of the Hyaluronate
Division since November 1996 and General Manager of the Oral Restorative
Division since November 1997. From June 1995 until January 1996, Mr. Allingham
served as Senior Vice President and Chief Financial Officer of Premier Salons
International, Inc., a leading private hair salon chain in North America. From
June 1993 until May 1995, Mr. Allingham served as Executive Vice President,
Chief Financial Officer and director of TitleWave Stores, Inc., a leading chain
retailer of home entertainment software. From July 1992 until May 1993, Mr.
Allingham was a management financial consultant. From June 1980 until June 1992,
Mr. Allingham held various positions with Krelitz Industries, Inc., a wholesale
distributor of pharmaceutical and healthcare products, most recently serving as
Executive Vice President, Chief Operating Officer, Chief Financial Officer and
director.
BRIAN J. KANE. Mr. Kane was appointed Vice President of New Business
Development and Marketing in December 1997. He had been Vice President of New
Business Development for the Company since July 1991. He joined the Company as
Vice President of Marketing in June 1986.
COLLEEN M. OLSON. Ms. Olson has been Vice President of Corporate
Administrative Operations of the Company since May 1991. Prior to that time, she
was Vice President of Human Resources and Administration from June 1990 to May
1991, and Director of Human Resources and Administration from October 1984 to
June 1990. She joined the Company in January 1980 as Office Manager.
ITEM 2. PROPERTIES
The Company's operations are all conducted in its 110,000 square foot
building in Chaska, Minnesota. The Company completed its facility expansion
during fiscal 1998. See "Management's Discussion and Analysis of Financial
Condition and Results of Operation".
ITEM 3. LEGAL PROCEEDINGS
Not applicable.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
Not applicable.
14
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
The Company's Common Stock is traded on the Nasdaq National Market under
the symbol LCBM. The following table sets forth for each quarter of fiscal 1998
and 1997 the range of high and low closing sale prices of the Common Stock on
the Nasdaq National Market. These quotations represent prices between dealers
and do not include retail mark-ups, markdowns or commissions and may not
represent actual transactions.
FISCAL YEAR LOW HIGH
----------- --- ----
1998
First Quarter....................................... $ 12 1/2 $ 18 3/4
Second Quarter...................................... 17 7/8 26 1/4
Third Quarter....................................... 18 23 3/8
Fourth Quarter...................................... 15 5/8 23 3/8
1997
First Quarter....................................... $ 16 $ 22 1/8
Second Quarter...................................... 15 1/8 20
Third Quarter....................................... 14 5/8 19 5/8
Fourth Quarter...................................... 11 1/2 16 1/8
The Company has not paid cash dividends on its Common Stock and does not
plan to pay cash dividends in the near future. The Company expects to retain any
future earnings to finance its business. The Company has a loan agreement which
restricts its ability to pay dividends. See Note D to Consolidated Financial
Statements.
At July 31, 1998, the Company had 677 shareholders of record.
On July 10, 1998, the Company issued 28,413 shares of Common Stock, with an
aggregate value of $465,000, to Bridger Biomed, Inc. ("Bridger") as partial
repayment of a note payable between the Company and Bridger. Such shares are
exempt from the registration requirements of the Securities Act pursuant to
Section 4(2) of the Securities Act.
15
ITEM 6. SELECTED FINANCIAL DATA
SELECTED CONSOLIDATED FINANCIAL DATA
(In thousands, except per share amounts)
The following sets forth selected historical financial data with respect to
the Company and its subsidiaries. The data given below as of and for the five
years ended June 30, 1998 has been derived from the Company's Consolidated
Financial Statements audited by Grant Thornton LLP, independent certified public
accountants. Such data should be read in conjunction with the Company's
Consolidated Financial Statements and Notes thereto included elsewhere herein
and "Management's Discussion and Analysis of Financial Condition and Results of
Operations."
YEARS ENDED JUNE 30,
--------------------------------------------------------------------
1998 1997 1996 1995 1994
---- ---- ---- ---- ----
STATEMENTS OF OPERATIONS DATA:
Net sales. . . . . . . . . . . . . . . . . . . . . . . $25,570 $18,913 $14,063 $10,018 $10,430
Costs of goods sold. . . . . . . . . . . . . . . . . . 10,941 9,052 9,173 7,900 6,004
------- ------- ------- ------- -------
Gross profit . . . . . . . . . . . . . . . . . . . . . 14,629 9,861 4,890 2,118 4,426
Operating Expenses
Research and development. . . . . . . . . . . . . . . 4,940 3,703 2,699 1,381 1,072
Marketing and sales . . . . . . . . . . . . . . . . . 6,889 5,464 4,356 3,038 2,645
General and administrative. . . . . . . . . . . . . . 3,345 2,986 2,861 2,382 2,100
Insurance proceeds, net . . . . . . . . . . . . . . . - - (754) - -
------- ------- ------- ------- -------
15,174 12,153 9,162 6,801 5,817
------- ------- ------- ------- -------
Loss from operations . . . . . . . . . . . . . . . . . (545) (2,292) (4,272) (4,683) (1,391)
Other income (expense) . . . . . . . . . . . . . . . . 778 1,259 272 (532) (1,406)
------- ------- ------- ------- -------
Net income (loss). . . . . . . . . . . . . . . . . . . $ 233 $(1,033) $(4,000) $(5,215) $(2,797)
------- ------- ------- ------- -------
------- ------- ------- ------- -------
Net income (loss) per common share
Basic . . . . . . . . . . . . . . . . . . . . . . $ .02 $ (.08) $ (.40) $ (.66) $ (.39)
------- ------- ------- ------- -------
------- ------- ------- ------- -------
Diluted . . . . . . . . . . . . . . . . . . . . . $ .02 $ (.08) $ (.40) $ (.66) $ (.39)
------- ------- ------- ------- -------
------- ------- ------- ------- -------
Weighted average common and common equivalent
shares outstanding
Basic . . . . . . . . . . . . . . . . . . . . . . 12,269 12,179 10,114 7,880 7,176
------- ------- ------- ------- -------
------- ------- ------- ------- -------
Diluted . . . . . . . . . . . . . . . . . . . . . 12,568 12,179 10,114 7,880 7,176
------- ------- ------- ------- -------
------- ------- ------- ------- -------
AS OF JUNE 30, 1998
--------------------------------------------------------------------
1998 1997 1996 1995 1994
---- ---- ---- ---- ----
BALANCE SHEET DATA:
Working Capital. . . . . . . . . . . . . . . . . $17,084 $26,848 $22,207 $ 3,987 $ 3,618
Total assets . . . . . . . . . . . . . . . . . . 66,948 65,509 64,429 25,522 24,063
Long-term obligations. . . . . . . . . . . . . . 6,658 7,596 7,193 7,888 9,051
Shareholders' equity . . . . . . . . . . . . . . 53,299 52,096 52,152 10,188 11,328
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
GENERAL
The Company develops, manufactures and markets medical and surgical devices
through its Hyaluronate and the Oral Restorative Divisions.
The Company has a number of relationships with corporate partners relating
to the development and marketing of hyaluronate-based products for a variety of
medical applications, as well as certain non-hyaluronate-based applications that
utilize the Company's specialized manufacturing capabilities. Currently, the
primary commercial application for the Company's
16
hyaluronate is as a component in ophthalmic surgical products marketed by Alcon
and Bausch & Lomb Surgical for cataract surgery. Sales to Alcon are made under a
supply agreement which extends through December 31, 1998. The agreement contains
minimum purchase requirements totaling $10.4 million, consisting of $3.2 million
in calendar year 1995 and $2.4 million in each of calendar years 1996 through
1998. Currently, the Company supplies Bausch & Lomb Surgical with aseptically
packaged syringes according to purchase orders. Bausch & Lomb Surgical is
marketing the Company's product in Europe and is awaiting approval from the FDA
on its PMA supplement in order to begin sales of the Company's product in the
United States. Initial sales of INTERGEL Solution occurred during fiscal 1998,
as Ethicon began marketing INTERGEL Solution in Europe. Sales of INTERGEL
Solution in the United States are dependent upon Pre-Market Approval by the FDA.
The Company's Oral Restorative Division markets a comprehensive line of
titanium-based dental implants for tooth replacement therapy. In May 1992, the
Company acquired the Sustain System from BII and subsequently, in July 1993,
acquired ISS, the manufacturer of the Restore System and the ISS line of
compatible components. The Company has enhanced and expanded these product lines
since their acquisition. The Oral Restorative Division also manufactures and
markets synthetic bone graft substitute products for the restoration of bone
tissue deterioration resulting from periodontal disease and tooth loss. The
Oral Restorative Division also markets other products for the regeneration of
bone and soft tissue. The Division's products are marketed in the United States
through the Company's direct sales force; in Italy through the Company's
subsidiary, Lifecore Biomedical SpA; and in other countries through
distributors.
RESULTS OF OPERATIONS
NET SALES. Net sales increased $6,657,000 or 35% in fiscal 1998 from
fiscal 1997, due to a $2,605,000 increase in sales to hyaluronate customers and
a $4,052,000 increase in sales to oral restorative customers.
Hyaluronate sales increased to $9,720,000 in fiscal 1998 from $7,115,000 in
fiscal 1997. Sales to Alcon were $4,761,000, $3,204,000, and $2,861,000 for
fiscal years 1998, 1997 and 1996. In fiscal year 1996, sales to Alcon were at
contract minimums. In fiscal years 1998 and 1997, Alcon purchased above its
contract minimum. Net sales to hyaluronate customers other than Alcon increased
$1,048,000 or 27% in fiscal 1998 from fiscal 1997. This increase was led mainly
by initial sales of INTERGEL Solution to Ethicon and general increases in other
areas. Sales to Bausch & Lomb Surgical were comparable in fiscal 1998 and
fiscal 1997, and are not expected to increase appreciably until the PMA
Supplement is approved allowing the sale of Lifecore-manufactured product in the
United States. Hyaluronate sales increased to $7,115,000 in fiscal 1997 from
$5,585,000 in fiscal 1996. The increase in hyaluronate sales in fiscal 1997
benefited from the increased sales to Alcon. Net sales to other hyaluronate
customers increased $1,187,000 or 44% in fiscal 1997 from fiscal 1996. This
increase was led mainly by sales to Bausch & Lomb Surgical which increased by
59% in fiscal 1997 from fiscal 1996.
Oral Restorative sales increased 34% to $15,850,000 in fiscal 1998 from
$11,798,000 in fiscal 1997. The increase primarily reflects the continued
market acceptance of the Company's implant products which increased by 26% and
the expanded product offerings in the tissue regeneration product line which
increased 109% in fiscal 1998 from fiscal 1997. Oral restorative product sales
increased 39% to $11,798,000 in fiscal 1997 from $8,478,000 in fiscal 1996.
This increase primarily reflects the continued market acceptance of the
Company's implant products, the effects of increased sales and marketing
activities in the domestic market, and increased sales internationally through
an expanded distributor network and at Lifecore Biomedical SpA.
GROSS PROFIT. Gross profit, as a percentage of net sales, increased to 57%
in fiscal 1998 from 52% in fiscal 1997 and 35% in fiscal 1996. The increases
resulted from expenses being spread over increased product sales and the
expanded utilization of the Company's aseptic and hyaluronate production
capacity. Gross profit, as a percentage of net sales for the oral restorative
products, was 60% in fiscal 1998 and fiscal 1997 and 54% in fiscal 1996. Gross
profit as a percent of net sales for the oral restorative products in fiscal
1998, exclusive of Alloderm Dermal Graft, increased by 2 percentage points.
However, this increase was offset by a lower gross profit margin from Alloderm
Dermal Graft, which was introduced in fiscal 1998. The increase in the gross
profit, as a percent of sales, in fiscal 1997 was principally from spreading
fixed expenses over increased oral restorative product sales and, to a lessor
extent, from lower raw material costs as a result of the ability to purchase in
larger quantities.
RESEARCH AND DEVELOPMENT. Research and development expenses increased
$1,237,000 or 33% in fiscal 1998 from fiscal 1997 and $1,004,000 or 37% in
fiscal 1997 from fiscal 1996. The increases in fiscal 1998 and fiscal 1997 were
principally a result of costs associated with human clinical trials on INTERGEL
Solution.
MARKETING AND SALES. Marketing and sales expenses increased by $1,425,000
or 26% in fiscal 1998 from fiscal 1997. The increase in expenses mainly
occurred in the Oral Restorative Division. The components of the increase in
fiscal 1998 were
17
$476,000 due to higher compensation costs for additional sales personnel and
commissions on an increased sales base, $477,000 for increased advertising and
marketing costs, $156,000 from higher travel and entertainment expenses due to
expanded sales personnel, and a general increase in other areas. Marketing and
sales expenses increased by $1,108,000 or 25% in fiscal 1997 from fiscal 1996.
The increase in expenses mainly occurred in the Oral Restorative Division. The
components of this increase in fiscal 1997 were $417,000 for increased
advertising and marketing costs, $363,000 due to higher compensation costs for
expanded sales personnel and commissions on an increased sales base, $137,000
from Lifecore Biomedical SpA for increased sales personnel and expanded
marketing efforts, and a general increase in telephone, travel and entertainment
expenses.
GENERAL AND ADMINISTRATIVE. General and administrative expenses increased
by $359,000 or 12% in fiscal 1998 from fiscal 1997. The increase resulted from
higher personnel related costs and the amortization of the TefGen membrane
product line purchase that occurred in May 1997. General and administrative
expenses increased by $125,000 or 4% in fiscal 1997 from fiscal 1996. The
increase in fiscal 1997 resulted mainly from higher personnel related costs,
including salaries, health insurance, recruiting and relocation expenses.
INSURANCE PROCEEDS, NET. In May 1996, the Company received net proceeds of
$754,000 on an insurance claim for product that was damaged in production as a
result of equipment failure.
OTHER INCOME (EXPENSE). Interest expense was lower in fiscal 1998 compared
to fiscal 1997 due to the capitalization of interest expense in conjunction with
the facility expansion project. Interest income was lower in fiscal 1998
compared to fiscal 1997 as a result of a lower average amount of cash to invest
than in fiscal 1997. Interest expense was lower in fiscal 1997 compared to
fiscal 1996 due to a lower amount of debt outstanding and the capitalization of
interest expense in conjunction with the facility expansion project. Interest
income was greater in fiscal 1997 compared to fiscal 1996 as a result of a
higher average amount of cash to invest than in fiscal 1996.
LIQUIDITY AND CAPITAL RESOURCES
Inventories consist mainly of finished hyaluronate and oral restorative
products and related raw materials. The portion of finished hyaluronate
inventory that is not expected to be consumed within the next twelve months is
classified as long-term. The finished hyaluronate inventory is maintained in a
frozen state and has a shelf life in excess of five years. Total inventory
increased $5,414,000 or 53% in fiscal 1998 from fiscal 1997 principally due to
building of hyaluronate inventory levels in anticipation of the demand for
INTERGEL Solution.
The Company has had significant operating cash flow deficits for the last
three fiscal years. As the Hyaluronate Division's sales continue to increase,
the Company's direct charges associated with excess plant capacity are
decreasing; however, research and development costs for INTERGEL Solution,
marketing and sales expenses for the oral restorative products, and personnel
costs are increasing. Obligations under a promissory note in connection with
the TefGen membrane product line acquisition total $1,600,000 for fiscal 1999.
A principal payment of $400,000 plus interest was made in July 1998 utilizing
the Company's common stock. The remaining amount may be paid in cash or the
Company's common stock at the Company's option. During the third quarter of
fiscal 1997, the Company satisfied its lease commitment with Johnson & Johnson
Finance Corporation by purchasing the equipment subject to the lease. The
Company paid approximately $5.1 million in exchange for the specialized
production equipment which Lifecore was utilizing under the operating lease.
The lease termination has favorably impacted ongoing financial operating costs.
The loan agreement between the Company and the holder of the industrial
development revenue bonds issued to finance the Company's Chaska, Minnesota
facility was amended in July 1998 to waive the fixed charge coverage ratio and
the cash flow coverage ratio through June 30, 1999. With respect to certain of
these covenants, the Company may be required to obtain further waivers for
fiscal 2000. There can be no assurance that future waivers will be granted to
the Company.
In January 1998, the Company entered into a $5,000,000 Credit Agreement and
Revolving Credit Note with a bank. The agreement allows for advances against
eligible securities and eligible accounts receivable, subject to a borrowing
base certificate. Interest is accrued at either the prime rate or the
Eurodollar Rate plus a basis point adjustment as defined in the Credit
Agreement. The Revolving Credit Note matures on October 31, 1998. The terms of
the agreement require the Company to comply with various financial covenants.
At June 30, 1998, the Company was in compliance or had obtained waivers for all
covenants.
18
During fiscal 1998 and 1997, the Company expanded its manufacturing and
distribution capabilities at its Chaska, Minnesota location. The expansion
included building and equipment expenditures for warehouse and distribution
capabilities and to scale-up aseptic-packaging facilities for finished products.
The expansion totaled approximately $19 million and was completed in June 1998.
The expansion was funded from the proceeds of investment maturities. This
expansion provides future capacity, but increases the level of fixed charges to
be absorbed by operations.
In fiscal 1996, the Company completed public offerings of the Common Stock,
providing net proceeds of approximately $45 million. The Company used the net
proceeds to expand its warehouse and distribution capabilities, to accelerate
the scale-up of aseptic-packaging facilities in anticipation of significant
commercial demand for finished hyaluronate products and for working capital in
fiscal 1997 and 1998.
The Company exercised its option under the ISS note payable to make the
final principal payment due December 15, 1996 in the form of the Company's
common stock. To satisfy the $450,000 amount due, 29,108 shares of common stock
were issued under the formula described in the note.
The Company's ability to generate positive cash flow from operations and
achieve profitability is dependent upon the continued expansion of revenue from
its hyaluronate and oral restorative businesses. Growth in the Hyaluronate
Division is unpredictable due to the complex governmental regulatory environment
for new medical products and the early stage of certain of these markets.
Similarly, expansion of the Company's Oral Restorative Division sales is also
dependent upon increased revenue from new and existing customers, as well as
successfully competing in a more mature market. With the completion of the
facility expansion, the Company expects its cash generated from anticipated
operations and the availability of the line of credit to satisfy cash flow needs
in the near term. No assurance can be given that the Company will attain and
maintain positive cash flow before its capital resources are exhausted. While
the Company's capital resources appear adequate today, unforeseen events, prior
to achieving and maintaining positive cash flow, could require additional
financing. If additional financing is necessary, no assurance can be given that
such financing will be available and, if available, will be on terms favorable
to the Company and its shareholders.
YEAR 2000 ISSUE
The Company has completed an assessment of Year 2000 compliance for its
critical operating and application systems. Through this assessment, no major
issues were discovered. The Company expects to be fully Year 2000 compliant by
December 31, 1998. The cost associated with the assessment and any
modifications necessary was less than $50,000.
Ultimately, the potential impact of the Year 2000 issue will depend not
only on the actions taken by the Company, but also on the way in which the Year
2000 issue is addressed by customers, vendors, service providers, utilities,
governmental agencies and other entities with which the Company does business.
The Company is communicating with these parties to learn how they are addressing
the Year 2000 issue and to evaluate any likely impact on the Company. The
Company has requested commitment dates from the various parties as to their Year
2000 readiness and delivery of compliant software and other products. This
process will continue into fiscal 1999. The Year 2000 efforts of third parties
are not within the Company's control, however, and their failure to respond to
Year 2000 issues successfully could result in business disruption and increased
operating cost for the Company. At the present time, it is not possible to
determine whether any such events are likely to occur, or to quantify any
potential negative impact they may have on the Company's future results of
operations and financial condition. The Company expects to assess its need for
contingency plans during 1999.
The foregoing discussion regarding the Year 2000 Project's timing,
effectiveness, implementation, and cost, contains forward-looking statements,
which are based on management's best estimates derived using assumptions. These
forward-looking statements involve inherent risks and uncertainties, and actual
results could differ materially from those contemplated by such statements.
Factors that might cause material differences include, but are not limited too,
the availability of key Year 2000 personnel, the Company's ability to locate and
correct all relevant computer codes, the readiness of third parties, and the
Company's ability to respond to unforeseen Year 2000 complications. Such
material differences could result in, among other things, business disruption,
operational problems, financial loss, legal liability and similar risks.
CAUTIONARY STATEMENT
Statements included in this Management's Discussion and Analysis of
Financial Condition and Results of Operations and elsewhere in this Form 10-K,
in the Letter to Shareholders contained in the Annual Report to Shareholders, in
future filings
19
by the Company with the Securities and Exchange Commission and in the Company's
press releases and oral statements made with the approval of authorized
executive officers, if the statements are not historical or current facts,
should be considered "forward-looking statements" made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995.
These statements are subject to certain risks and uncertainties that could cause
actual results to differ materially from historical earnings and those presently
anticipated or projected. The Company wishes to caution readers not to place
undue reliance on any such forward-looking statements, which speak only as of
the date made. The following important factors, among others, in some cases
have affected and in the future could affect the Company's actual results and
could cause its actual financial performance to differ materially from that
expressed in any forward-looking statement: (i) uncertainty of successful
development of the Company's INTERGEL Solution, including the necessary PMA from
the FDA, and of other new hyaluronate products; (ii) the Company's reliance on
corporate partners to develop new products on a timely basis and to market the
Company's existing and new hyaluronate products effectively; (iii) possible
limitations on the Company's ability to meet anticipated significant commercial
demand for INTERGEL Solution on a timely basis; and (iv) intense competition in
the markets for the Company's principal products. The foregoing list should not
be construed as exhaustive, and the Company disclaims any obligation
subsequently to revise any forward-looking statements to reflect events or
circumstances after the date of such statements or to reflect the occurrence of
anticipated or unanticipated events.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The consolidated financial statements are listed under Item 14 of this
report.
Summarized unaudited quarterly financial data for 1998 and 1997 is as
follows:
Quarter
---------------------------------------------------------
First Second Third Fourth
---- ------ ----- ------
Year ended June 30, 1998
Net sales. . . . . . . . . . . . . . . . . . . . . . $ 5,214,000 $ 6,258,000 $ 7,512,000 $ 6,586,000
Gross profit . . . . . . . . . . . . . . . . . . . . 2,687,000 3,420,000 4,317,000 4,205,000
Net income (loss). . . . . . . . . . . . . . . . . . (903,000) (175,000) 806,000 505,000
Net income (loss) per share
Basic. . . . . . . . . . . . . . . . . . . . $ (.07) $(.01) $ .07 $ .04
Diluted. . . . . . . . . . . . . . . . . . . $ (.07) $(.01) $ .06 $ .04
Weighted average common and common
equivalent shares outstanding
Basic. . . . . . . . . . . . . . . . . . . . 12,225,025 12,239,438 12,274,096 12,319,705
Diluted. . . . . . . . . . . . . . . . . . . 12,225,025 12,239,438 12,686,287 12,595,930
Year ended June 30, 1997
Net sales. . . . . . . . . . . . . . . . . . . . . . $ 3,568,000 $ 4,684,000 $ 4,611,000 $ 6,050,000
Gross profit . . . . . . . . . . . . . . . . . . . . 1,470,000 2,173,000 2,858,000 3,360,000
Net income (loss). . . . . . . . . . . . . . . . . . (654,000) (543,000) 27,000 137,000
Net income (loss) per share
Basic. . . . . . . . . . . . . . . . . . . . $ (.05) $ (.04) $ - $ .01
Diluted. . . . . . . . . . . . . . . . . . . $ (.05) $ (.04) $ - $ .01
Weighted average common and common
equivalent shares outstanding
Basic. . . . . . . . . . . . . . . . . . . . 12,131,046 12,180,372 12,180,648 12,221,082
Diluted. . . . . . . . . . . . . . . . . . . 12,131,046 12,180,372 12,529,710 12,429,360
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
None.
20
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
Information concerning director nominees is set forth in the section
entitled "Election of Directors" in the Company's Proxy Statement for its 1998
Annual Meeting of Shareholders to be held November 12, 1998, which is
incorporated herein by reference. See also "Executive Officers of the
Registrant" in Item 1 above.
ITEM 11. EXECUTIVE COMPENSATION
Information concerning executive compensation is set forth in the section
entitled "Executive Compensation" in the Company's Proxy Statement for its 1998
Annual Meeting of Shareholders which is incorporated herein by reference.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
Security ownership of certain owners and management is set forth in the
section entitled "Security Ownership of Certain Beneficial Owners and
Management" in the Company's Proxy Statement for its 1998 Annual Meeting of
Shareholders which is incorporated herein by reference.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
Not Applicable.
21
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K
(a) Documents filed as part of the report
1. Consolidated Financial Statements
Form 10-K
Page Reference
----------------
Report of Independent Certified Public Accountants. . . . . . . . . . . . . . F-1
Consolidated Balance Sheets - June 30, 1998 and 1997. . . . . . . . . . . . . F-2
Consolidated Statements of Operations - years ended June 30, 1998,
1997 and 1996 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-4
Consolidated Statements of Cash Flows - years ended June 30, 1998,
1997 and 1996 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-5
Consolidated Statements of Shareholders' Equity - years ended
June 30, 1998, 1997 and 1996. . . . . . . . . . . . . . . . . . . . . . . . . F-6
Notes to Consolidated Financial Statements. . . . . . . . . . . . . . . . . . F-7 through F-19
2. Consolidated Financial Statement Schedules
Schedule II - Valuation and Qualifying Accounts . . . . . . . . . . . . . . . S-1
(b) Reports on Form 8-K
None
(c) Exhibits and Exhibit Index
DESCRIPTION
2.1 Stock Purchase Agreement between ISS and Lifecore dated July 28,
1993 (includes $2 million 5% Promissory Note dated July 28, 1993
as Exhibit A and Security Agreement as Exhibit B) (Pursuant to
Rule 24b-2, certain portions of this Exhibit have been deleted
and filed separately with the Commission) (incorporated by
reference to Exhibit 2.1 to Form 8-K dated July 8, 1993)
3.1 Restated Articles of Incorporation, as amended (incorporated by
reference to Exhibit 19(a) to Amendment No. 1 on Form 8, dated
July 13, 1988, to Form 10-Q for the quarter ended December 31,
1987), as amended by Amendment No. 2 (incorporated by reference
to Exhibit 3.1 to Form 10-K for the year ended June 30, 1997)
3.2 Amended Bylaws, (incorporated by reference to Exhibit 3.2 to
Form 10-K/A for the year ended June 30, 1995)
3.3 Form of Rights Agreement, dated as of May 23, 1996, between the
Company and Norwest Bank Minnesota, National Association
(incorporated by reference to Exhibit 1 to the Company's Form
8-A Registration Statement dated May 31, 1996)
4.1 Form of Common Stock Certificate (incorporated by reference to
Exhibit 4.1 to 1987 S-2 Registration Statement
[File No. 33-12970])
22
10.1 Loan Agreement dated as of September 1, 1990 between the City
of Chaska and the Company (incorporated by reference from
Exhibit 4.2 to the Registrant's Form 10-K for the year ended
June 30, 1990, as amended on Form 8 dated October 12, 1990) as
amended on June 10, 1991 and July 24, 1991 (incorporated by
reference from Exhibit 10.2 to the Registrant's Amendment No.
1 to Form 1991 S-2 Registration Statement [File No. 33-41291])
as amended on August 3, 1992 (incorporated by reference to
Exhibit 10.1 to Form 10-K for the year ended June 30, 1992) as
amended on July 28, 1994 (incorporated by reference to Exhibit
10.1 to Form 10-K for the year ended June 30, 1994), as
amended on July 27, 1995 (incorporated by reference to Exhibit
10.1 to Form 10-K for the year ended June 30, 1995), as
amended on July 8, 1996, (incorporated by reference to Exhibit
10.1 to Form 10-K for the year ended June 30, 1996), as
amended on July 1, 1997 (incorporated by reference to Exhibit
10.1 to Form 10-K for the year ended June 30, 1997), as
amended on June 5, 1998, filed herewith
10.2 Trust Indenture dated as of September 1, 1990 from the City of
Chaska to Norwest Bank Minnesota, N.A., as Trustee
(incorporated by reference from Exhibit 4.3 to the
Registrant's Form 10-K for the year ended June 30, 1990, as
amended on Form 8 dated October 12, 1990)
10.3 Combination Mortgage, Security Agreement and Fixture Financing
Statement dated as of September 1, 1990 from the Company to
Norwest Bank Minnesota, N.A., as Trustee (incorporated by
reference from Exhibit 4.4 to the Registrant's Form 10-K for
the year ended June 30, 1990, as amended on Form 8 dated
October 12, 1990)
10.4 Contract for Private Redevelopment dated as of September 1,
1990 between the Company and Chaska Economic Development
Authority (incorporated by reference from Exhibit 4.5 to the
Registrant's Form 10-K for the year ended June 30, 1990, as
amended on Form 8 dated October 12, 1990)
10.5 Hyaluronate Purchase Agreement dated March 28, 1990 between
the Company and Alcon (incorporated by reference to Exhibit 10
to Form 8-K dated April 10, 1990, as amended on Form 8 dated
May 23, 1990) as amended on July 17, 1992, (Certain
information has been deleted from this exhibit and filed
separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment under Rule
24b-2) (incorporated by reference to Exhibit 10.5 to Form 10-K
for the year ended June 30, 1992)
10.6 Employment Agreement dated June 10, 1991 with James W. Bracke
(incorporated by reference to Exhibit 10.11 to 1991 S-2
Registration Statement [File No. 33-41291]), as amended by
letter agreement dated on August 14, 1995 (incorporated by
reference to Exhibit 10.6 to Form 10-K for the year ended June
30, 1995), as amended by letter agreement dated November 14,
1996 (incorporated by reference to Exhibit 10.1 to Form 10-Q
for the quarter ended December 31, 1997)
10.7 Form of Indemnification Agreement entered into between the
Company and directors and officers (incorporated by reference
to Exhibit 10.7 to Form 10-K for the year ended June 30, 1995)
10.8 1987 Stock Option Plan (incorporated by reference to Exhibit
4(a) to S-8 Registration Statement [File No. 33-26065])
10.9 1987 Employee Stock Purchase Savings Plan (incorporated by
reference to Exhibit 4(a) to S-8 Registration Statement
[File No. 33-19288])
10.10 1990 Employee Stock Purchase Savings Plan (incorporated by
reference to Exhibit 4(a) to S-8 Registration Statement
[File No. 33-32984])
10.11 1990 Stock Plan (incorporated by reference to Exhibit 4(a) to
S-8 Registration Statement [File No. 33-38914]) as amended by
Amendment No. 1 (incorporated by reference to Exhibit 10.13 to
Form 10-K for the year ended June 30, 1994), as amended by
Amendment No. 2 (incorporated by reference to Exhibit 10.11 to
Form 10-K for the year ended June 30, 1997)
23
10.12 Conveyance, License, Development and Supply Agreement dated
August 8, 1994 between Lifecore Biomedical, Inc. and Ethicon,
Inc. (pursuant to Rule 24b-2, certain portions of this Exhibit
have been omitted and filed separately with the Commission)
(incorporated by reference to Exhibit 10.14 to Form 10-K for
the year ended June 30, 1994)
10.13 1996 Stock Option Plan (incorporated by reference to Exhibit
4.1 to S-8 Registration Statement [File No. 333-18515])
10.14 Amendment No. 2 to Hyaluronate Purchase Agreement dated
December 4, 1992 between Lifecore Biomedical, Inc. and Alcon
Surgical, Inc. (pursuant to Rule 24b-2, certain portions of
this Exhibit have been omitted and filed separately with the
Commission) (incorporated by reference to Exhibit 28 to Form
8-K dated December 4, 1992)
10.15 Amendment No. 3 to Hyaluronate Purchase Agreement dated May
12, 1993 between Lifecore Biomedical, Inc. and Alcon Surgical,
Inc. (pursuant to Rule 24b-2, certain portions of this Exhibit
have been omitted and filed separately with the Commission)
(incorporated by reference to Exhibit 10.18 to Form 10-K for
the year ended June 30, 1993 as amended on Form 10-K/A dated
December 15, 1994)
10.16 Letter Agreement dated October 28, 1992 between the Company
and Bio-Interfaces, Inc. (incorporated by reference to Exhibit
28.1 to Form 8-K dated October 5, 1992)
10.17 Stock Purchase Agreement dated August 8, 1994 between Lifecore
Biomedical, Inc. and Johnson and Johnson Development
Corporation, (incorporated by reference to Exhibit 10.20 to
Form 10-K for the year ended June 30, 1994)
10.18 Amendment No. 4 to Hyaluronate Purchase Agreement dated
November 29, 1994, between Lifecore Biomedical, Inc. and Alcon
Laboratories, Inc. (pursuant to Rule 24b-2, certain portions
of this Exhibit have been omitted and filed separately with
the Commission) (incorporated by reference to Exhibit 10.21 to
Form 10-Q for the quarter ended December 31, 1994)
10.19 Supply Agreement dated December 7, 1994 between Lifecore
Biomedical, Inc. and IOLAB Corporation (now Bausch & Lomb
Surgical) (pursuant to Rule 24b-2, certain portions of this
Exhibit have been omitted and filed separately with the
Commission) (incorporated by reference to Exhibit 10.20 to
Form 10-K for the year ended June 30, 1995)
10.20 Standard Form of Agreement Between Owner and Construction
Manager dated June 1, 1996 between Lifecore Biomedical, Inc.
and Marshall Contractors, Inc., (incorporated by reference to
Exhibit 10.21 to Form 10-K for the year ended June 30, 1997)
10.21 General Conditions of the Contract for Construction relating
to the Standard Form of Agreement Between Owner and
Construction Manager dated June 1, 1996 between Lifecore
Biomedical, Inc. and Marshall Contractors, Inc., (incorporated
by reference to Exhibit 10.22 to Form 10-K for the year ended
June 30, 1997)
10.22 Credit Agreement dated January 15, 1998 between the Company
and First Bank National Association, (incorporated by
reference to Exhibit 10.2 to Form 10-Q for the quarter ended
December 31, 1997)
10.23 Revolving Credit Note dated January 15, 1998 between the
Company and First Bank National Association, (incorporated by
reference to Exhibit 10.3 to Form 10-Q for the quarter ended
December 31, 1997)
10.24 Security Agreement dated January 15, 1998 by the Company in
favor of First Bank National Association, (incorporated by
reference to Exhibit 10.4 to Form 10-Q for the quarter ended
December 31, 1997)
24
10.25 Custodial Pledge and Security Agreement dated January 15, 1998
by and between the Company, Norwest Investment Services, Inc.,
and First Bank National Association, (incorporated by
reference to Exhibit 10.5 to Form 10-Q for the quarter ended
December 31, 1997)
10.26 First amendment to Credit Agreement dated June 30, 1998 by and
between the Company and U.S. Bank National Association, filed
herewith
23.1 Consent of Grant Thornton LLP
27 Financial Data Schedule
99 Risk Factors
25
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
LIFECORE BIOMEDICAL, INC.
Dated: August 27, 1998 By /s/ JAMES W. BRACKE
---------------------------
James W. Bracke, Ph.D.
PRESIDENT, CHIEF EXECUTIVE OFFICER
AND SECRETARY
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
Registrant and in capacities and on the dates indicated.
Dated: August 27, 1998 By /s/ DENNIS J. ALLINGHAM
---------------------------------
Dennis J. Allingham
EXECUTIVE VICE PRESIDENT AND CHIEF
FINANCIAL OFFICER
(PRINCIPAL FINANCIAL OFFICER)
Dated: August 27, 1998 By /s/ JAMES W. BRACKE
---------------------------------
James W. Bracke, Ph.D.
PRESIDENT, CHIEF EXECUTIVE OFFICER
(PRINCIPAL EXECUTIVE OFFICER),
SECRETARY AND DIRECTOR
Dated: August 27, 1998 By /s/ ORWIN L. CARTER
---------------------------------
Orwin L. Carter
DIRECTOR
Dated: August 27, 1998 By /s/ JOAN L. GARDNER
---------------------------------
Joan L. Gardner
DIRECTOR
Dated: August 27, 1998 By /s/ THOMAS H. GARRETT
---------------------------------
Thomas H. Garrett
DIRECTOR
Dated: August 27, 1998 By /s/ JOHN C. HEINMILLER
---------------------------------
John C. Heinmiller
DIRECTOR
Dated: August 27, 1998 By /s/ DONALD W. LARSON
---------------------------------
Donald W. Larson
DIRECTOR
Dated: August 27, 1998 By /s/ RICHARD W. PERKINS
---------------------------------
Richard W. Perkins
DIRECTOR
Dated: August 27, 1998 By /s/ MARK T. SELLNOW
---------------------------------
Mark T. Sellnow
CONTROLLER (PRINCIPAL ACCOUNTING
OFFICER)
26
(This page has been left blank intentionally.)
27
REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS
Shareholders and Board of Directors
Lifecore Biomedical, Inc.
We have audited the accompanying consolidated balance sheets of Lifecore
Biomedical, Inc. (a Minnesota corporation) and subsidiaries as of June 30, 1998
and 1997, and the related consolidated statements of operations, shareholders'
equity, and cash flows for each of the three years in the period ended June 30,
1998. These financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these financial
statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly,
in all material respects, the consolidated financial position of Lifecore
Biomedical, Inc. and subsidiaries as of June 30, 1998 and 1997, and the
consolidated results of their operations and their consolidated cash flows for
each of the three years in the period ended June 30, 1998, in conformity with
generally accepted accounting principles.
We have also audited Schedule II of Lifecore Biomedical, Inc. and
subsidiaries for each of the three years in the period ended June 30, 1998. In
our opinion, this schedule presents fairly, in all material respects, the
information required to be set forth therein.
/s/ GRANT THORNTON LLP
Minneapolis, Minnesota
July 31, 1998
F - 1
CONSOLIDATED BALANCE SHEETS
JUNE 30,
ASSETS
1998 1997
------------ ------------
CURRENT ASSETS
Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . $ 2,092,000 $ 1,371,000
Short-term investments. . . . . . . . . . . . . . . . . . . . . . 3,953,000 16,630,000
Accounts receivable, less allowances. . . . . . . . . . . . . . . 4,609,000 4,792,000
Inventories . . . . . . . . . . . . . . . . . . . . . . . . . . . 12,918,000 8,440,000
Prepaid expenses. . . . . . . . . . . . . . . . . . . . . . . . . 503,000 1,432,000
------------ ------------
Total current assets . . . . . . . . . . . . . . . . . . . . 24,075,000 32,665,000
PROPERTY, PLANT AND EQUIPMENT - AT COST
Land. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 249,000 249,000
Building. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22,721,000 7,977,000
Equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14,915,000 9,492,000
Land and building improvements. . . . . . . . . . . . . . . . . . 1,955,000 1,510,000
------------ ------------
39,840,000 19,228,000
Less accumulated depreciation . . . . . . . . . . . . . . . . . . (6,948,000) (5,483,000)
------------ ------------
32,892,000 13,745,000
Construction-in-progress and advance deposits . . . . . . . . . . - 5,265,000
------------ ------------
32,892,000 19,010,000
OTHER ASSETS
Intangibles . . . . . . . . . . . . . . . . . . . . . . . . . . . 5,786,000 6,306,000
Long-term investments . . . . . . . . . . . . . . . . . . . . . . - 3,960,000
Security deposits . . . . . . . . . . . . . . . . . . . . . . . . 848,000 786,000
Inventories . . . . . . . . . . . . . . . . . . . . . . . . . . . 2,775,000 1,839,000
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 572,000 943,000
------------ ------------
9,981,000 13,834,000
------------ ------------
$ 66,948,000 $ 65,509,000
------------ ------------
------------ ------------
F - 2
LIABILITIES AND SHAREHOLDERS' EQUITY
1998 1997
------------ ------------
CURRENT LIABILITIES
Current maturities of long-term obligations . . . . . . . . . . . $ 1,733,000 $ 918,000
Accounts payable. . . . . . . . . . . . . . . . . . . . . . . . . 3,783,000 3,613,000
Accrued compensation. . . . . . . . . . . . . . . . . . . . . . . 804,000 638,000
Accrued expenses. . . . . . . . . . . . . . . . . . . . . . . . . 671,000 648,000
------------ ------------
Total current liabilities. . . . . . . . . . . . . . . . . . 6,991,000 5,817,000
LONG-TERM OBLIGATIONS. . . . . . . . . . . . . . . . . . . . . . . . . 6,658,000 7,596,000
COMMITMENTS AND CONTINGENCIES. . . . . . . . . . . . . . . . . . . . . - -
SHAREHOLDERS' EQUITY
Preferred stock - authorized, 25,000,000 shares of $1.00 stated
value; none issued. . . . . . . . . . . . . . . . . . . . . . . . - -
Preferred stock, Series A Junior Participating - authorized,
500,000 shares of $1.00 par value; none issued. . . . . . . . . . - -
Common stock - authorized, 50,000,000 shares of
$.01 stated value; issued and outstanding, 12,321,709 and
12,222,722 shares at June 30, 1998 and 1997 . . . . . . . . . . . 123,000 122,000
Additional paid-in capital . . . . . . . . . . . . . . . . . . . . . . 85,084,000 84,115,000
Accumulated deficit. . . . . . . . . . . . . . . . . . . . . . . . . . (31,908,000) (32,141,000)
------------ ------------
53,299,000 52,096,000
------------ ------------
$66,948,000 $65,509,000
------------ ------------
------------ ------------
The accompanying notes are an integral part of these statements.
F - 3
CONSOLIDATED STATEMENTS OF OPERATIONS
YEARS ENDED JUNE 30,
1998 1997 1996
------------ ------------ ------------
Net sales. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ 25,570,000 $ 18,913,000 $ 14,063,000
Cost of goods sold . . . . . . . . . . . . . . . . . . . . . . . . . . 10,941,000 9,052,000 9,173,000
------------ ------------ ------------
Gross profit. . . . . . . . . . . . . . . . . . . . . . . . . . . 14,629,000 9,861,000 4,890,000
Operating expenses
Research and development. . . . . . . . . . . . . . . . . . . . . 4,940,000 3,703,000 2,699,000
Marketing and sales . . . . . . . . . . . . . . . . . . . . . . . 6,889,000 5,464,000 4,356,000
General and administrative. . . . . . . . . . . . . . . . . . . . 3,345,000 2,986,000 2,861,000
Insurance proceeds, net . . . . . . . . . . . . . . . . . . . . . -- -- (754,000)
------------ ------------ ------------
15,174,000 12,153,000 9,162,000
------------ ------------ ------------
Loss from operations . . . . . . . . . . . . . . . . . . . . (545,000) (2,292,000) (4,272,000)
Other income (expense)
Interest income . . . . . . . . . . . . . . . . . . . . . . . . . 900,000 1,900,000 1,086,000
Interest expense. . . . . . . . . . . . . . . . . . . . . . . . . (122,000) (641,000) (814,000)
------------ ------------ ------------
778,000 1,259,000 272,000
------------ ------------ ------------
NET INCOME (LOSS). . . . . . . . . . . . . . . . . . . . . . . . . . . $ 233,000 $ (1,033,000) $ (4,000,000)
------------ ------------ ------------
------------ ------------ ------------
Net income (loss) per common share
Basic. . . . . . . . . . . . . . . . . . . . . . . . . . . . $ .02 $ (.08) $ (.40)
------------ ------------ ------------
------------ ------------ ------------
Diluted. . . . . . . . . . . . . . . . . . . . . . . . . . . $ .02 $ (.08) $ (.40)
------------ ------------ ------------
------------ ------------ ------------
Weighted average common and common equivalent shares
outstanding
Basic. . . . . . . . . . . . . . . . . . . . . . . . . . . . 12,268,644 12,179,008 10,114,149
------------ ------------ ------------
------------ ------------ ------------
Diluted. . . . . . . . . . . . . . . . . . . . . . . . . . . 12,568,215 12,179,008 10,114,149
------------ ------------ ------------
------------ ------------ ------------
The accompanying notes are an integral part of these statements.
F - 4
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED JUNE 30,
1998 1997 1996
------------ ------------ ------------
Cash flows from operating activities:
Net income (loss). . . . . . . . . . . . . . . . . . . . . . . . . . . $ 233,000 $ (1,033,000) $ (4,000,000)
Adjustments to reconcile net income (loss) to net cash used in
operating activities:
Depreciation and amortization. . . . . . . . . . . . . . . . . . . . 2,013,000 1,406,000 1,015,000
Allowance for doubtful accounts. . . . . . . . . . . . . . . . . . . 60,000 -- 67,000
Changes in operating assets and liabilities
Accounts receivable . . . . . . . . . . . . . . . . . . . . . . . 123,000 (2,466,000) (795,000)
Inventories . . . . . . . . . . . . . . . . . . . . . . . . . . . (5,414,000) (2,311,000) (1,810,000)
Prepaid expenses. . . . . . . . . . . . . . . . . . . . . . . . . 929,000 (632,000) (396,000)
Accounts payable. . . . . . . . . . . . . . . . . . . . . . . . . 170,000 2,457,000 410,000
Accrued liabilities . . . . . . . . . . . . . . . . . . . . . . . 189,000 8,000 457,000
Customers' deposits . . . . . . . . . . . . . . . . . . . . . . . -- (1,952,000) (2,788,000)
------------ ------------ ------------
Total adjustments. . . . . . . . . . . . . . . . . . . . . . (1,930,000) (3,490,000) (3,840,000)
------------ ------------ ------------
Net cash used in operating activities. . . . . . . . . . . . . . . . . (1,697,000) (4,523,000) (7,840,000)
Cash flows from investing activities:
Purchases of property, plant and equipment . . . . . . . . . . . . . (15,347,000) (11,338,000) (1,147,000)
Purchases of intangibles . . . . . . . . . . . . . . . . . . . . . . (28,000) (840,000) (33,000)
Purchases of investments . . . . . . . . . . . . . . . . . . . . . . (3,976,000) (11,379,000) (67,832,000)
Maturities of investments. . . . . . . . . . . . . . . . . . . . . . 20,613,000 25,844,000 32,748,000
Decrease (increase) in security deposits . . . . . . . . . . . . . . (62,000) 2,000 234,000
Decrease (increase) in other assets. . . . . . . . . . . . . . . . . 371,000 341,000 (420,000)
------------ ------------ ------------
Net cash provided by (used in) investing activities. . . . . . . . . . 1,571,000 2,630,000 (36,450,000)
------------ ------------ ------------
Cash flows from financing activities:
Payments of long-term obligations. . . . . . . . . . . . . . . . . . (123,000) (527,000) (1,136,000)
Proceeds from issuance of common stock . . . . . . . . . . . . . . . -- -- 45,305,000
Proceeds from stock options exercised. . . . . . . . . . . . . . . . 970,000 527,000 659,000
------------ ------------ ------------
Net cash provided by financing activities. . . . . . . . . . . . . . . 847,000 -- 44,828,000
------------ ------------ ------------
Net increase (decrease) in cash and cash equivalents . . . . . . . . . 721,000 (1,893,000) 538,000
Cash and cash equivalents at beginning of year . . . . . . . . . . . . 1,371,000 3,264,000 2,726,000
------------ ------------ ------------
Cash and cash equivalents at end of year . . . . . . . . . . . . . . . $ 2,092,000 $ 1,371,000 $ 3,264,000
------------ ------------ ------------
------------ ------------ ------------
Supplemental disclosure of cash flow information:
Cash paid during the year for:
Interest . . . . . . . . . . . . . . . . . . . . . . . . . . $ 710,000 $ 737,000 $ 784,000
The accompanying notes are an integral part of these statements.
F - 5
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
COMMON STOCK
---------------------------
ADDITIONAL
SHARES PAID-IN ACCUMULATED
ISSUED AMOUNT CAPITAL DEFICIT
------------ ------------ ------------ ------------
Balances at July 1, 1995 . . . . . . . . . . . . . . . . . . . . . . . 7,972,167 $ 80,000 $ 37,216,000 $(27,108,000)
Exercise of stock options and
employee stock purchase
savings plan, net of 628 shares
surrendered in payment . . . . . . . . . . . . . . . . . . . 119,804 1,000 658,000 --
Proceeds from sale of common stock. . . . . . . . . . . . . . . . 4,030,000 40,000 45,265,000 --
Net loss for the year ended
June 30, 1996. . . . . . . . . . . . . . . . . . . . . . . . -- -- -- (4,000,000)
------------ ------------ ------------ ------------
Balances at June 30, 1996. . . . . . . . . . . . . . . . . . . . . . . 12,121,971 121,000 83,139,000 (31,108,000)
Exercise of stock options and
employee stock purchase savings
plan, net of 1,588 shares
surrendered in payment . . . . . . . . . . . . . . . . . . . 71,643 1,000 545,000 --
Issuance of common stock issued as
payment of debt. . . . . . . . . . . . . . . . . . . . . . . 29,108 -- 431,000 --
Net loss for the year ended
June 30, 1997. . . . . . . . . . . . . . . . . . . . . . . . -- -- -- (1,033,000)
------------ ------------ ------------ ------------
Balances at June 30, 1997 12,222,722 122,000 84,115,000 (32,141,000)
Exercise of stock options and
employee stock purchase savings
plan, net of 1,419 shares
surrendered in payment . . . . . . . . . . . . . . . . . . . 98,987 1,000 969,000 --
Net income for the year ended
June 30, 1998 . . . . . . . . . . . . . . . . . . . . . . . . -- -- -- 233,000
------------ ------------ ------------ ------------
Balances at June 30, 1998. . . . . . . . . . . . . . . . . . . . . . . 12,321,709 $ 123,000 $ 85,084,000 $(31,908,000)
------------ ------------ ------------ ------------
------------ ------------ ------------ ------------
The accompanying notes are an integral part of these statements.
F - 6
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Lifecore Biomedical, Inc. (the "Company"), develops, manufactures, and
markets surgically implantable materials and devices through its two divisions,
the Hyaluronate Division and the Oral Restorative Division. The Hyaluronate
Division's manufacturing facility is located in Chaska, Minnesota and markets
its products through OEM and contract manufacturing alliances in the fields of
ophthalmology, veterinary and wound care management. The Oral Restorative
Division markets its products through direct sales in the United States and
Italy and through distributors in other foreign countries.
In preparing financial statements in conformity with generally accepted
accounting principles, management is required to make estimates and assumptions
that affect the reported amounts of assets and liabilities and the disclosure of
contingent assets and liabilities at the date of the financial statements and
revenues and expenses during the reporting periods. Actual results could differ
from those estimates.
A summary of significant accounting policies consistently applied in the
preparation of the financial statements follows:
1. CONSOLIDATION POLICY
The consolidated financial statements include the accounts of the Company
and its wholly-owned subsidiaries, Implant Support Systems, Inc. and Lifecore
Biomedical SpA. All intercompany balances and transactions have been eliminated
in consolidation.
2. CASH AND CASH EQUIVALENTS
The Company considers all highly liquid temporary investments with original
maturities of three months or less to be cash equivalents. At June 30, 1998 and
1997, principally all of the Company's cash and cash equivalents are invested in
a money market fund.
3. INVESTMENTS
The Company has invested its excess cash in commercial paper, government
agencies and medium term corporate notes. These investments are classified as
held-to-maturity given the Company's intent and ability to hold the securities
to maturity and are carried at amortized cost. Investments that have maturities
of less than one year have been classified as short-term investments.
F - 7
NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CONTINUED
At June 30, 1998 and 1997, amortized cost approximates fair value of
held-to-maturity investments which consist of the following:
1998 1997
----------- -----------
Short-term investments:
Medium term corporate notes $ 3,953,000 $12,800,000
Commercial paper -- 2,627,000
U.S. Government Agencies -- 1,203,000
----------- -----------
3,953,000 16,630,000
Long-term investments:
Medium term corporate notes -- 3,960,000
----------- -----------
-- 3,960,000
----------- -----------
$ 3,953,000 $20,590,000
----------- -----------
----------- -----------
4. ACCOUNTS RECEIVABLE
The Company grants credit to customers in the normal course of business,
but generally does not require collateral or any other security to support
amounts due. The Company's customers are located primarily throughout the United
States, Europe, and South America. Management performs on-going credit
evaluations of its customers. Accounts receivable balances from customers
located in Europe and South America were 42% and 44% of total receivables at
June 30, 1998 and 1997. The Company maintains allowances for potential credit
losses which were $346,000 and $286,000 at June 30, 1998 and 1997.
5. INVENTORIES
Inventories are stated at the lower of cost (first-in, first-out method)
or market. Inventory not expected to be consumed within one year is classified
as a long-term asset. Inventories consist of the following:
AS OF JUNE 30,
-------------------------
. . . . . . . . 1998 1997
----------- -----------
Raw materials . . . . . . . . $ 4,236,000 $ 2,819,000
Work-in-process . . . . . . . . 204,000 205,000
Finished goods . . . . . . . . 11,253,000 7,255,000
----------- -----------
$15,693,000 $10,279,000
----------- -----------
----------- -----------
F - 8
NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CONTINUED
6. DEPRECIATION
Depreciation is provided in amounts sufficient to charge the cost of
depreciable assets to operations over their estimated service lives principally
on a straight-line method for financial reporting purposes and on straight-line
and accelerated methods for income tax reporting purposes. Depreciation expense
was approximately $ 1,465,000, $ 990,000 and $ 628,000 for the years ended June
30, 1998, 1997 and 1996. Lives used in straight-line depreciation for financial
reporting purposes are as follows:
NUMBER OF
YEARS
---------
Building . . . . . . . . . . . . . . . . . . . . . 18-25
Equipment. . . . . . . . . . . . . . . . . . . . . 3-15
Land and building improvements . . . . . . . . . . 18
7. INTANGIBLES
Intangibles consist primarily of the cost of the technology and regulatory
rights related to the Sustain Dental Implant System product line acquired in
May 1992, the goodwill related to the July 1993 acquisition of Implant Support
Systems, Inc., and the cost of the technology and regulatory rights related to
the TefGen Regenerative Membrane product line acquired in May 1997.
On an ongoing basis, the Company reviews the valuation and amortization of
intangibles to determine possible impairment by comparing the carrying value to
projected undiscounted future cash flows of the related assets. The cost of the
technology and regulatory rights and the goodwill are being amortized on the
straight-line method over 15 years, their estimated useful lives. Accumulated
amortization of intangibles was $2,171,000 and $1,647,000 at June 30, 1998 and
1997.
8. OTHER ASSETS
Included within other assets are costs incurred to register patents and
trademarks which are capitalized as incurred. Amortization of these costs
commences when the related patent or trademark is granted. The costs are
amortized over the estimated useful life of the patent or trademark, not to
exceed 17 years. Patents and trademarks consist of the following:
AS OF JUNE 30,
------------------------
1998 1997
--------- ---------
Patents. . . . . . . . . . . . . . . . . $ 191,000 $ 169,000
Trademarks . . . . . . . . . . . . . . . 63,000 61,000
--------- ---------
254,000 230,000
Less accumulated amortization. . . . . . (111,000) (97,000)
--------- ---------
$ 143,000 $ 133,000
--------- ---------
--------- ---------
F - 9
NOTE A - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - CONTINUED
9. REVENUE RECOGNITION AND PRODUCT WARRANTY
The Company recognizes revenue when product is shipped or otherwise
accepted by the customer. Under the terms of a contract covering sales of
ophthalmic hyaluronate, the Company's product is under warranty against
non-compliance with product specifications. A provision is made for the
estimated cost of replacing or further processing any product not complying with
the warranted product specifications.
10. NET INCOME (LOSS) PER COMMON SHARE
On December 31, 1997, the Company adopted Statement of Financial Accounting
Standards No. 128 - "Earnings Per Share." As required by Statement No. 128, all
previously reported income (loss) per share data have been restated to conform
to the provisions of Statement No. 128.
The Company's basic net income (loss) per share amounts have been computed
by dividing net income (loss) by the weighted average number of outstanding
common shares. The Company's diluted net income (loss) per share is computed by
dividing net income (loss) by the weighted average number of outstanding common
shares and common share equivalents relating to stock options, when dilutive.
For the fiscal year ended June 30, 1998, 299,571 shares of common stock
equivalents were included in the computation of diluted net income per share.
For the fiscal years ended June 30, 1997 and 1996, the common share equivalents
that would have been included in the computation of diluted net income per share
were 267,480 and 265,495, had net income been achieved.
Options to purchase 283,125, 55,000, and 62,500 shares of common stock with
a weighted average exercise price of $20.03, $18.57, and $16.75 were outstanding
at June 30, 1998, 1997, and 1996, but were excluded from the computation of
common share equivalents because their exercise prices were greater than the
average market price of the common shares.
11. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENT
The Financial Accounting Standards Board has issued Statement No. 130
"Reporting Comprehensive Income" and Statement No. 131 "Disclosures about
Segments of an Enterprise and Related Information" which are effective for
fiscal year 1999. Statement No. 130 will require the Company to display an
amount representing total comprehensive income, as defined by the statement, as
part of the Company's basic financial statements. Comprehensive income will
include items such as unrealized gains or losses on certain investment
securities and foreign currency items. Statement No. 131 will require the
Company to disclose financial and other information about its business segments,
their products and services, geographic areas, major customers, revenues,
profits, assets, and other information.
The adoption of these standards is not expected to have a material effect
on the consolidated financial statements of the Company.
F - 10
NOTE B - ACQUISITION OF TEFGEN MEMBRANE PRODUCT LINE
In May 1997, the Company acquired the technology and regulatory rights in
the TefGen membrane product line from Bridger Biomed, Inc. As consideration for
the $2,400,000 acquisition price, the Company paid $800,000 in cash and issued a
note payable for $1,600,000. The note, as amended, bears interest at 6% per
annum with a principal payment of $400,000 plus interest due in July 1998 and a
principal payment of $1,200,000 plus interest due in May 1999. The principal
payments may be made in cash or the Company's common stock at the Company's
option. If the Company chooses its common stock as the form of payment, the
note holder has certain registration rights. The Company exercised its option
to make the July 1998 principal payment of $400,000 plus interest in the form of
the Company's common stock. To satisfy the $400,000 amount plus interest due,
28,413 shares of common stock were issued in July 1998 under the formula
described in the note. The note is secured by the purchased assets. The cost
of the technology and regulatory rights is being amortized on a straight-line
basis over 15 years.
NOTE C - LINE OF CREDIT
On January 15, 1998, the Company entered into a $5,000,000 Credit Agreement
and Revolving Credit Note with a bank. The agreement allows for advances
against eligible securities and eligible accounts receivable, subject to a
borrowing base certificate. Interest is accrued at either the prime rate or the
Eurodollar Rate plus a basis point adjustment as defined in the Credit
Agreement. The effective interest rate at June 30, 1998 was 7.74%. The
Revolving Credit Note matures on October 31, 1998. At June 30, 1998, there were
no amounts outstanding under this line of credit. The terms of the agreement
require the Company to comply with various financial covenants including minimum
quick ratio debt service coverage and maximum debt to tangible net worth. At
June 30, 1998, the Company was in compliance with or had obtained waivers for
all covenants.
NOTE D - LONG-TERM OBLIGATIONS
Long-term obligations consist of the following:
AS OF JUNE 30,
--------------------------
1998 1997
----------- -----------
Industrial development revenue bonds . . . $ 6,669,000 $ 6,749,000
Note payable . . . . . . . . . . . . . . . 1,600,000 1,600,000
Other. . . . . . . . . . . . . . . . . . . 122,000 165,000
----------- -----------
8,391,000 8,514,000
Less current maturities. . . . . . . . . . (1,733,000) (918,000)
----------- -----------
$ 6,658,000 $ 7,596,000
----------- -----------
----------- -----------
INDUSTRIAL DEVELOPMENT REVENUE BONDS
On September 28, 1990, the Company completed a $7,000,000 transaction to
finance its manufacturing and administrative facility through the issuance of
30-year industrial development revenue bonds by the municipality where the
facility is located. The bonds are collateralized by a first mortgage on the
facility and bear interest at 10.25%. The Company is required to make debt
service payments on the bonds of approximately $775,000 per year for fiscal
years 1996 through 2021. The payments are required to be made monthly to a
sinking fund. At June 30, 1998, the Company has approximately $700,000 on
deposit with
F - 11
NOTE D - LONG-TERM OBLIGATIONS - CONTINUED
the bond trustee to cover the reserve fund requirement. The Company has the
right to redeem the bonds commencing September
1, 1998 upon the payment of the outstanding principal balance plus accrued
interest and a premium. The premium is 8% of the principal amount during the
year commencing September 1, 1998 and declines during subsequent years.
The terms of the loan agreement require the Company to comply with various
financial covenants including minimum current ratio, fixed charges coverage and
cash flow coverage requirements and maximum debt to net worth limitation. The
fixed charges coverage and cash flow coverage requirements have been waived by
the bondholder through fiscal 1999. The debt to net worth ratio covenant has the
effect of restricting the payment of cash dividends or repurchases of common
stock.
NOTE PAYABLE
On July 28, 1993, the Company acquired all of the outstanding shares of
common stock of Implant Support Systems, Inc. ("ISS"). The Company paid
$682,000 in cash, issued a $2,000,000 note payable and assumed certain
liabilities. The payment terms of the note payable were amended in September
1994. The note, as amended, required interest to be paid quarterly at 5% with
principal payments of $700,000 paid during fiscal 1995, $850,000 paid in October
1995 and $450,000 which was paid on December 15, 1996. The Company exercised
its option under the ISS note payable to make the final principal payment due
December 15, 1996 in the form of the Company's common stock. To satisfy the
$450,000 amount due, 29,108 shares of common stock were issued under the formula
described in the note.
In May 1997, the Company issued a note payable for $1,600,000 as part of
the consideration paid to the seller of the TefGen membrane product line (see
Note B).
At June 30, 1998 and 1997, the carrying amounts of long-term obligations
approximate the fair value of these obligations. The aggregate minimum annual
principal payments of long-term obligations for the years ending June 30 are as
follows:
1999 . . . . . . . . . . . . . . . . . . . . $1,733,000
2000 . . . . . . . . . . . . . . . . . . . . 143,000
2001 . . . . . . . . . . . . . . . . . . . . 146,000
2002 . . . . . . . . . . . . . . . . . . . . 120,000
2003 . . . . . . . . . . . . . . . . . . . . 135,000
Thereafter . . . . . . . . . . . . . . . . . 6,114,000
----------
$8,391,000
----------
----------
At June 30, 1998 and 1997, the Company capitalized $691,000 and $87,000 of
interest expense in conjunction with the facility expansion at its Chaska,
Minnesota location.
NOTE E - OPERATING LEASES
The Company leased equipment under an operating lease with Johnson &
Johnson Finance Corporation ("JJFC"), an affiliate of the Company's customers,
Ethicon, Inc. ("Ethicon") and Johnson & Johnson Medical, Ltd. JJFC is also an
affiliate of
F - 12
NOTE E - OPERATING LEASES - CONTINUED
Johnson & Johnson Development Corporation, a shareholder of the Company (see
Note K). In February 1997, the Company satisfied this lease commitment by
purchasing the equipment subject to the lease. The purchase price of the
equipment was approximately $5.1 million. Additionally, the Company had entered
into operating leases with a financial institution for approximately $900,000 of
furniture and fixtures. During the year ended June 30, 1996, the Company
purchased from the financial institution the furniture and fixtures subject to
the operating leases. Operating lease expense was approximately $665,000 and
$1,825,000 for the years ended June 30, 1997 and 1996.
NOTE F - INCOME TAXES
Deferred tax assets and liabilities represent the tax effects, based on
current tax law, of future deductible or taxable amounts attributable to events
that have been recognized in the financial statements. Deferred tax assets
(liabilities) consist of the following at June 30:
1998 1997
------------- -------------
Deferred tax assets
Net operating loss carryforward. . . . . . . . . $ 9,330,000 $ 9,855,000
Capital loss carryforward. . . . . . . . . . . . 377,000 377,000
Tax credit carryforward. . . . . . . . . . . . . 426,000 289,000
Inventories. . . . . . . . . . . . . . . . . . . 1,370,000 989,000
Other. . . . . . . . . . . . . . . . . . . . . . 304,000 263,000
------------- -------------
Total deferred tax assets. . . . . . . . . . . . 11,807,000 11,773,000
Deferred tax liabilities
Depreciation . . . . . . . . . . . . . . . . . . (1,042,000) (752,000)
------------- -------------
Total deferred tax liabilities . . . . . . . . . (1,042,000) (752,000)
------------- -------------
Net deferred tax asset before valuation allowance. 10,765,000 11,021,000
Valuation allowance. . . . . . . . . . . . . . . . (10,765,000) (11,021,000)
------------- -------------
Net deferred tax asset . . . . . . . . . . . . . . $ -- $ --
------------- -------------
------------- -------------
The deferred tax asset valuation allowance decreased $256,000 during 1998, as
these benefits were realized.
At June 30, 1998, the Company had net operating loss carryforwards of
approximately $26,200,000 for tax reporting purposes, which expire as follows:
1999 . . . . . . . . . . . . . $ 92,000
2000 . . . . . . . . . . . . . 2,084,000
2001 . . . . . . . . . . . . . 2,022,000
2002 . . . . . . . . . . . . . 1,641,000
2003 . . . . . . . . . . . . . 557,000
2004 - 2012. . . . . . . . . . 19,804,000
The Company also has general business credit carryforwards of approximately
$288,000, which expire in 1999 through 2012.
F - 13
NOTE F - INCOME TAXES - CONTINUED
Differences between income tax expense (benefit) and amounts derived by
applying the statutory federal income tax rate to income (loss) before income
taxes are as follows for fiscal years ending June 30:
1998 1997 1996
---- ---- ----
U.S. federal statutory rate. . . . . . . 34.0% (34.0)% (34.0)%
Change in valuation allowance. . . . . . (34.0) 34.0 34.0
------ ------ ------
-- -- --
------ ------ ------
NOTE G - SHAREHOLDERS' EQUITY
OFFERINGS OF COMMON STOCK
In October 1995, the Company received net proceeds of approximately
$19,852,000 from the sale of 2,200,000 shares of its common stock through a
public offering. In November 1995, the Company received net proceeds of
approximately $3,010,000 when the underwriters purchased an additional 330,000
shares of common stock related to the over-allotment option.
In April 1996, the Company completed the sale of 1,500,000 shares of its
common stock and received net proceeds of approximately $22,443,000 through a
Regulation S offering to qualified investors outside the United States.
STOCK OPTION PLANS
The Company has three stock option plans. In November 1987, the
shareholders adopted the 1987 Stock Plan (the "1987 Plan") to provide for
options to be granted to certain eligible salaried employees and non-employee
members of the Board of Directors. A total of 300,000 shares of common stock
are reserved for issuance under the 1987 Plan. In November 1990, the
shareholders adopted the 1990 Stock Plan (the "1990 Plan") to provide for
options to be granted to certain eligible employees, non-employee members of the
Board of Directors and other non-employee persons as defined in the 1990 Plan.
In November 1993, the 1990 Plan was amended to provide for a total of 1,000,000
shares of common stock reserved for issuance under the 1990 Plan. In November
1996, the shareholders adopted the 1996 Stock Plan (the "1996 Plan") to provide
for options to be granted to certain eligible employees, non-employee members of
the Board of Directors and other non-employee persons as defined in the 1996
Plan. A total of 3,000,000 shares of common stock are reserved for issuance
under the 1996 Plan. Options will be granted under all plans at exercise prices
which are determined by a committee as appointed by the Board of Directors.
Options granted to date under all plans have been at fair market value. Each
grant awarded specifies the period for which the options are exercisable and
provides that the options shall expire at the end of such period.
F - 14
NOTE G - SHAREHOLDERS' EQUITY - CONTINUED
Option transactions under the 1987, 1990 and 1996 Stock Plans during the
three years ended June 30, 1998 are summarized as follows:
NUMBER OF WEIGHTED AVERAGE
SHARES EXERCISE PRICE
---------- ----------------
Outstanding at July 1, 1995. . . . . . . . . . . . . . . . . 629,419 $ 7.00
Granted. . . . . . . . . . . . . . . . . . . . . . . . . . 181,500 12.45
Exercised. . . . . . . . . . . . . . . . . . . . . . . . . (98,257) 5.59
Canceled . . . . . . . . . . . . . . . . . . . . . . . . . (30,417) 8.82
--------- ---------
Outstanding at June 30, 1996 . . . . . . . . . . . . . . . . 682,245 8.74
Granted. . . . . . . . . . . . . . . . . . . . . . . . . . 876,168 16.74
Exercised. . . . . . . . . . . . . . . . . . . . . . . . . (63,507) 6.82
Canceled . . . . . . . . . . . . . . . . . . . . . . . . . (45,625) 9.67
--------- ---------
Outstanding at June 30, 1997 . . . . . . . . . . . . . . . . 1,449,281 13.63
Granted. . . . . . . . . . . . . . . . . . . . . . . . . . 334,000 19.24
Exercised. . . . . . . . . . . . . . . . . . . . . . . . . (89,225) 9.24
Canceled . . . . . . . . . . . . . . . . . . . . . . . . . (53,000) 15.98
--------- ---------
Outstanding at June 30, 1998 . . . . . . . . . . . . . . . . 1,641,056 $ 14.83
--------- ---------
--------- ---------
NUMBER OF WEIGHTED AVERAGE
SHARES EXERCISE PRICE
---------- ----------------
Options exercisable at June 30:
1998 . . . . . . . . . . . . . . . . . . . . . . . . . . . 762,723 $12.28
1997 . . . . . . . . . . . . . . . . . . . . . . . . . . . 529,745 10.49
1996 . . . . . . . . . . . . . . . . . . . . . . . . . . . 331,520 8.10
The following tables summarizes information concerning currently outstanding
and exercisable stock options:
OPTIONS OUTSTANDING
RANGE OF NUMBER WEIGHTED AVERAGE REMAINING WEIGHTED AVERAGE EXERCISE
EXERCISE PRICES OUTSTANDING CONTRACTUAL LIFE PRICE
--------------- ----------- ---------------- -----
$2.63 - 3.94 88,533 3.4 years $3.42
3.95 - 5.91 81,780 5.8 years 5.51
5.92 - 8.86 71,500 5.4 years 7.05
8.87 - 13.29 201,800 6.4 years 10.92
13.30 - 19.93 1,078,443 8.2 years 17.00
19.94 - 24.00 119,000 9.3 years 21.38
---------
1,641,056
---------
---------
F - 15
NOTE G - SHAREHOLDERS' EQUITY - CONTINUED
OPTIONS EXERCISABLE
RANGE OF NUMBER WEIGHTED AVERAGE
EXERCISE PRICES EXERCISABLE EXERCISE PRICE
--------------- ----------- --------------
$2.63 - 3.94 82,658 $3.49
3.95 - 5.91 71,405 5.52
5.92 - 8.86 67,750 7.02
8.87 - 13.29 132,467 10.42
13.30 - 19.93 387,318 16.50
19.94 - 24.00 21,125 21.29
-------
762,723
-------
-------
The weighted average fair value of options granted in 1998, 1997 and 1996
was $12.61, $11.80 and $8.53 per share. The fair value of each option grant is
estimated on the date of grant using the Black-Scholes option pricing model with
the following weighted average assumptions used for grants in 1998, 1997 and
1996: no dividend yield; risk-free rate of return of 6%; volatility of 66.2%,
72.8%, and 74.5%; and an average term of 6.0 years, 6.4 years and 5.9 years.
The Company's 1998, 1997 and 1996 proforma net loss and basic net loss per share
would have been $1,559,000, $2,768,000 and $4,234,000 or $.13, $.23 and $.42 per
share had the fair value method been used for valuing options granted during
1998, 1997 and 1996. These effects may not be representative of the future
effects of applying the fair value method.
EMPLOYEE STOCK PURCHASE SAVINGS PLAN
The 1990 Employee Stock Purchase Savings Plan ("ESPSP") provides for the
purchase by eligible employees of Company common stock at a price equal to 85%
of the market price on either the anniversary date of such plan's commencement
or the termination date of the plan, whichever is lower. Participants may
authorize payroll deductions up to 10% of their base salary during the plan year
to purchase the stock. Since inception of the ESPSP a total of 98,862 shares
have been issued, including 10,931 shares for approximately $168,000 in 1998,
9,374 shares for approximately $142,000 during 1997 and 21,725 shares for
approximately $111,000 during 1996. At June 30, 1998, the Company had 51,138
shares reserved for future issuance under the ESPSP.
SHAREHOLDER RIGHTS PLAN
In May 1996 the Board of Directors unanimously adopted a shareholder rights
plan designed to ensure that all of the Company's shareholders receive fair and
equal treatment in the event of any proposal to acquire the Company. The Board
declared a distribution of one Right for each share of common stock outstanding
on June 15, 1996. Each Right entitles the holder to purchase 1/100th of a share
of a new series of Junior Participating Preferred Stock of Lifecore at an
initial exercise price of $110.00. Initially, the Rights will be attached to
the common stock and will not be exercisable. They become exercisable only
following the acquisition by a person or group, without the prior consent of the
Company's Board of Directors, of 15 percent or more of the Company's voting
stock, or following the announcement of a tender offer or exchange offer to
acquire an interest of 15 percent or more.
In the event that the Rights become exercisable, each Right will entitle
the holder to purchase, at the exercise price, common stock with a market value
equal to twice the exercise price and, should the Company be acquired, each
Right would entitle the holder to purchase, at the exercise price, common stock
of the acquiring company with a market value equal to twice the
F - 16
NOTE G - SHAREHOLDERS' EQUITY - CONTINUED
exercise price. Rights owned by the acquiring person would become void. In
certain specified instances, the Rights may be redeemed by the Company. If not
redeemed, they would expire on June 15, 2006.
NOTE H - COMMITMENTS AND CONTINGENCIES
CONSTRUCTION AGREEMENTS
The Company has completed the expansion of its manufacturing and
distribution capabilities at its Chaska, Minnesota location. The expansion
included building and equipment expenditures for warehouse and distribution
capabilities, and aseptic-packaging facilities for finished products.
Construction-in-progress and advance deposits relating to the expansion of
approximately $5,265,000 were incurred through June 30, 1997. At June 30, 1998,
the expansion assets were placed in service. At June 30, 1998 and 1997, firm
purchase commitments related to the expansion of approximately $1,770,000 and
$2,161,000 have been recorded in accounts payable.
ROYALTY AGREEMENTS
The Company has entered into agreements which provide for royalty payments
based on a percentage of net sales of certain products. Royalty expense under
these agreements was $191,000, $153,000, and $78,000 for the years ended
June 30, 1998, 1997 and 1996.
SEVERANCE AGREEMENTS
The Company has an agreement with each officer that provides severance pay
benefits if there is a change in control of the Company (as defined) and the
officer is involuntarily terminated (as defined). The maximum contingent
liability under these agreements at June 30, 1998 is approximately $1,266,000.
NOTE I - EMPLOYEE BENEFIT PLAN
The Company has a 401(k) profit sharing plan for eligible employees.
Contributions by the Company are determined by the Board of Directors. There
have been no Company contributions since the inception of the plan.
NOTE J - SEGMENT INFORMATION
The Company's two business segments are the manufacturing, marketing and
selling of products containing hyaluronate (the "Hyaluronate Division") and oral
restorative products (the "Oral Restorative Division").
Currently, products containing hyaluronate are sold primarily to customers
pursuant to supply agreements. Sales to Alcon under such agreements were 19%,
17% and 20% of total sales in 1998, 1997 and 1996.
The Company's Oral Restorative Division markets products directly to
clinicians and dental laboratories in the United States and Italy and primarily
through distributorship arrangements in other foreign locations.
F - 17
NOTE J - SEGMENT INFORMATION - CONTINUED
Sales to customers located principally in Europe and South America
accounted for 35%, 35% and 30% of total Company sales during the years ended
June 30, 1998, 1997 and 1996. The operations of the Company's Italian
subsidiary, Lifecore Biomedical SpA, have not been material to the consolidated
financial statements.
Segment information for the Company is as follows:
YEARS ENDED JUNE 30,
-----------------------------------------
1998 1997 1996
----------- ----------- -----------
Net sales
Hyaluronate products . . . . . . . . . . . . . $ 9,720,000 $ 7,115,000 $ 5,585,000
Oral restorative products. . . . . . . . . . . 15,850,000 11,798,000 8,478,000
----------- ----------- -----------
$25,570,000 $18,913,000 $14,063,000
----------- ----------- -----------
----------- ----------- -----------
Income (loss) from operations
Hyaluronate products . . . . . . . . . . . . . $ (918,000) $(1,877,000) $(3,472,000)
Oral restorative products. . . . . . . . . . . 373,000 (415,000) (800,000)
----------- ----------- -----------
$ (545,000) $(2,292,000) $(4,272,000)
----------- ----------- -----------
----------- ----------- -----------
Capital expenditures
Hyaluronate products . . . . . . . . . . . . . $15,070,000 $11,112,000 $ 798,000
Oral restorative products. . . . . . . . . . . 277,000 226,000 349,000
----------- ----------- -----------
$15,347,000 $11,338,000 $ 1,147,000
----------- ----------- -----------
----------- ----------- -----------
Depreciation and amortization expense
Hyaluronate products . . . . . . . . . . . . . $ 1,343,000 $ 878,000 $ 561,000
Oral restorative products. . . . . . . . . . . 670,000 528,000 454,000
----------- ----------- -----------
$ 2,013,000 $ 1,406,000 $ 1,015,000
----------- ----------- -----------
----------- ----------- -----------
AS OF JUNE 30,
--------------------------
1998 1997
----------- -----------
Identifiable assets
Hyaluronate products . . . . . . . . . . . . . $45,159,000 $27,576,000
Oral restorative products. . . . . . . . . . . 15,744,000 15,972,000
General corporate. . . . . . . . . . . . . . . 6,045,000 21,961,000
----------- -----------
$66,948,000 $65,509,000
----------- -----------
----------- -----------
F - 18
NOTE K - AGREEMENTS
Lifecore and Ethicon have entered into a Conveyance, License, Development
and Supply Agreement (the "Ethicon Agreement"). Additionally, Lifecore, Ethicon
and JJDC, a subsidiary of Johnson & Johnson, have entered into a Stock Purchase
Agreement.
Under the terms of the Ethicon Agreement, Ethicon transferred to Lifecore
its ownership in certain technology related to research and development
previously conducted on the Company's sodium hyaluronate material. The
technology transferred to Lifecore includes written technical documents related
to Ethicon's research and development of a product to inhibit the formation of
postsurgical adhesions. These documents include product specifications, methods
and techniques, technology, know-how and certain patent applications. Lifecore
has assumed responsibility for continuing the anti-adhesion development project
including conducting human clinical trials on INTERGEL-TM- Adhesion Prevention
Solution (formerly called LUBRICOAT Gel), a second generation hyaluronate-based
product. Lifecore has granted Ethicon exclusive worldwide marketing rights
through 2008 to the products developed by Lifecore within defined fields of use.
Under the terms of the Stock Purchase Agreement, JJDC purchased 757,396
unregistered shares of Lifecore common stock for total consideration of $4.0
million consisting of $2.6 million cash and $1.4 million conversion of a
customer deposit from Ethicon held by Lifecore. Lifecore granted JJDC
registration rights for these shares.
The Company has made and continues to make a significant investment in the
development and testing of INTERGEL-TM- Adhesion Prevention Solution, a product
designed to reduce the incidence of postsurgical adhesions. The product is
currently undergoing human clinical trials to develop the data necessary to
apply to the United States Food and Drug Administration ("FDA") for approval to
market the product for commercial application. However, even if the product is
successfully developed and the Company receives approval from the FDA, there can
be no assurance that it will receive market acceptance. Failure to achieve
significant sales of the product could have a material adverse effect on future
prospects for the Company's operations.
NOTE L - INSURANCE PROCEEDS
In May 1996, the Company received net proceeds of $754,000 on an insurance
claim for product that was damaged in production as a result of an equipment
failure.
NOTE M - LEGAL PROCEEDINGS
The Company is subject to various legal proceedings in the normal course of
business. Management believes that these proceedings will not have a material
adverse effect on the consolidated financial statements.
F - 19
LIFECORE BIOMEDICAL, INC. AND SUBSIDIARIES
SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS
ADDITIONS
---------------------------
COLUMN A COLUMN B COLUMN C COLUMN D COLUMN E
- ----------- ------------ --------------------------- ------------ --------------
BALANCE AT CHARGED TO CHARGED TO
BEGINNING COSTS AND OTHER BALANCE AT END
DESCRIPTION OF PERIOD EXPENSES ACCOUNTS DEDUCTIONS OF PERIOD
- ----------- ------------ ------------ ----------- ------------ --------------
Year ended June 30, 1998
Accounts receivable
allowance. . . . . . . . . . . $286,000 $ 63,000 $ -- $ (3,000) (A) $346,000
Year ended June 30, 1997
Accounts receivable
allowance. . . . . . . . . . . 286,000 56,000 -- (56,000) (A) 286,000
Year ended June 30, 1996
Accounts receivable
allowance. . . . . . . . . . . 219,000 77,000 -- (10,000) (A) 286,000
___________
(A) Deductions represent accounts receivable balances written-off during the
year.
S - 1